Document:

Exhibit 10.1

 

EXECUTION VERSION

 

SPONSOR SUPPORT AGREEMENT

 

This SPONSOR SUPPORT AGREEMENT
(this “Agreement”) is entered into as of May 1, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited
company (the “Company”), Montes Archimedes Acquisition Corp., a Delaware corporation (“MAAC”),
Patient Square Capital LLC, a Delaware limited liability company (the “MAAC Sponsor”), and solely for purposes of Sections
1(b), 1(d), 4, 5, 8(a) and (b), 9 (solely for purposes of his or her representations or
warranties therein), 10 through 13 and 14 through 23 (to the extent related to the foregoing sections) the
Insiders (as defined below). Each of the Company, MAAC, the MAAC Sponsor and each of the Insiders are sometimes referred to herein individually
as a “Party” and collectively as the “Parties.” Each of the MAAC Sponsor and each of the Insiders
are sometimes referred to herein individually as a “Shareholder.” Except as otherwise specified herein, capitalized
terms used but not otherwise defined herein shall have the meanings ascribed to them in the Business Combination Agreement (as defined
below).

 

WHEREAS, concurrently
with the execution of this Agreement, MAAC, the Company and Rhine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary
of the Company (“Merger Sub”), entered into that certain Business Combination Agreement (as amended, supplemented or
otherwise modified from time to time in accordance with its terms, the “Business Combination Agreement”);

 

WHEREAS, the Business
Combination Agreement contemplates that, on the terms and subject to the conditions therein, (a) on the Closing Date prior to the Closing,
the Company will consummate the Company Pre-Closing Steps, and (b) on the Closing Date promptly following consummation of the Company
Pre-Closing Steps, Merger Sub will merge with and into MAAC (the “Merger”), with MAAC as the surviving corporation
in the Merger and, after giving effect to such Merger, becoming a wholly-owned Subsidiary of the Company (collectively, and together with
the other transactions contemplated by the Business Combination Agreement and the Ancillary Documents, the “Transactions”);

 

WHEREAS, reference
is hereby made to the following Contracts (collectively, the “Affected Agreements”):

 

(A)       that
certain Letter Agreement dated October 6, 2020 and delivered by the MAAC Sponsor to MAAC (the “Sponsor Letter”);

 

(B)       those
certain Letter Agreements, dated October 6, 2020, and delivered by each of George Barrett, James Momtazee, Maria Walker and Stephen Oesterle
(each, an “Insider” and, collectively, the “Insiders”) to MAAC (each, an “Insider Letter”
and, collectively, the “Insider Letters”);

 

(C)       that
certain Warrant Agreement dated October 6, 2020 between MAAC and Continental Stock Transfer & Trust Company, a New York corporation,
as warrant agent (the “Warrant Agent”) (the “Warrant Agreement”); and

 

(D)       that
certain Registration and Stockholder Rights Agreement dated October 6, 2020 (the “MAAC Registration Rights Agreement”)
by and among MAAC, the MAAC Sponsor and each of the other Holders (as such term is defined therein).

 

     

     

    

 

WHEREAS, as of the
date hereof, each Shareholder, in its respective capacity as such, is the holder of record and the “beneficial owner” (within
the meaning of Rule 13d-3 under the Exchange Act) of (i) the number of MAAC Class A Shares, (ii) private placement warrants (the
 “Warrants”) to purchase an aggregate number of MAAC Class A Shares and/or (iii) the number of MAAC Class B Shares,
in each case, set forth on Exhibit A attached hereto opposite such person’s name on such Exhibit (collectively, with
respect to each Shareholder, the “Subject Company Securities”);

 

WHEREAS, as part of
the Transactions, each of the MAAC Class A Shares and the MAAC Class B Shares will be converted into Company Post-Closing Common Shares
on the terms and conditions set forth in the Business Combination Agreement;

 

WHEREAS, in connection
with the Transactions, and concurrently with the execution of this Agreement and the Business Combination Agreement, (a) the Company and
the MAAC Sponsor entered into that certain Lock-Up Agreement (as amended, supplemented or otherwise modified from time to time in accordance
with its terms, the “Sponsor Lock-Up Agreement”), and (b) the Company, on the one hand, and certain Company Shareholders,
on the other hand, entered into those certain Lock-Up Agreements (as amended, supplemented or otherwise modified from time to time in
accordance with their applicable terms, collectively, the “Significant Company Shareholder Lock-Up Agreements” and,
together with the Sponsor Lock-Up Agreement, collectively, the “Lock-Up Agreements”);

 

WHEREAS, in consideration
for the benefits to be received by the MAAC Sponsor and each of the Insiders under the terms of the Business Combination Agreement and
as a material inducement to the Company and MAAC agreeing to enter into and consummate the transactions contemplated by the Business Combination
Agreement, the MAAC Sponsor and each of the Insiders agrees to enter into this Agreement and to be bound by the applicable agreements,
covenants and obligations contained in this Agreement; and

 

WHEREAS, the Parties
acknowledge and agree that the Company and MAAC would not have entered into and agreed to consummate the transactions contemplated by
the Business Combination Agreement without each of the Shareholders entering into this Agreement and agreeing to be bound by the applicable
agreements, covenants and obligations contained in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows:

 

1.                 
Sponsor Letter and Insider Letters. The Company, MAAC, the MAAC Sponsor (in the case of clauses (a), (b), (c) and (e)) and
each Insider (in the case of clauses (b) and (d), as it relates to the Insider Letter to which he or she is a party) hereby agree as follows:

 

(a)               The
Sponsor Letter provides in Section 1 thereof that MAAC shall not enter into a definitive agreement regarding a Business Combination
(as defined therein) without the prior written consent of the MAAC Sponsor. The Transactions constitute a Business Combination for
purposes of the Sponsor Letter and the MAAC Sponsor hereby consents to entry into the Business Combination Agreement.

 

    2 

     

    

 

(b)              
The Sponsor Letter provides in Section 2 thereof, and each Insider Letter provides in Section 1 thereof, for certain requirements
of the MAAC Sponsor and the Insiders in respect of a Business Combination (in each case, as defined therein), including in respect of
voting all MAAC Shares beneficially owned by the MAAC Sponsor and by the Insiders, as applicable, in favor of such Business Combinations
and forgoing redemption rights in respect thereof. The Transactions constitute a Business Combination for purposes of the Sponsor Letter
and each Insider Letter and the MAAC Sponsor and each Insider will comply with its, his or her respective obligations under Section 2
of the Sponsor Letter or Section 1 of its, his or her Insider Letter, as applicable.

 

(c)              
Subject to, and conditioned upon the occurrence and effective as of, the Effective Time, Section 6 of the Sponsor Letter shall
be amended and restated to provide in its entirety as follows: “[Reserved].”

 

(d)              
Subject to, and conditioned upon the occurrence and effective as of, the Effective Time, Section 5 of each Insider Letter
shall be amended and restated to provide in its entirety as follows: “[Reserved].”

 

(e)              
Section 7 of the Sponsor Letter is hereby amended and restated to provide in its entirety as follows: “[Reserved].”
For the avoidance of doubt, if the Business Combination Agreement is terminated in accordance with its terms, then this clause (e) (and
the amendment and restatement contemplated by this clause (e)) shall be of no further force and effect and Section 7 shall be reinstated
and effective from and after such time.

 

2.                 
Earn-Out Shares.

 

(a)              
Subject to, and conditioned upon the occurrence of and effective immediately after the Effective Time, (i) 20% of the number of
Company Post-Closing Common Shares issued to the MAAC Sponsor upon the conversion of MAAC Class B Shares (rounded up to the nearest whole
share) shall be subject to the provisions set forth below in this Section 2 (such Company Post-Closing Common Shares,
the “20% Earn-Out Shares”), (ii) 10% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor
upon the conversion of MAAC Class B Shares (rounded up to the nearest whole share) shall be subject to the provisions set forth below
in this Section 2 (such Company Post-Closing Common Shares, the “10% Earn-Out Shares” and, together
with the 20% Earn-Out Shares, the “Earn-Out Shares”) and (iii) the remaining 70% of the number of Company Post-Closing
Common Shares issued to the MAAC Sponsor upon the conversion of MAAC Class B Shares (rounded down to the nearest whole share) shall not
be subject to the provisions set forth below in this Section 2 (such Company Post-Closing Common Shares, the “Retained
Shares”).

 

(b)               Subject
to, and conditioned upon the occurrence of and effective immediately after the Effective Time, the Earn-Out Shares shall be unvested
and subject to the restrictions and forfeiture provisions set forth in this Section 2. The Earn-Out Shares shall vest and
become free of the provisions set forth in this Section 2 at such time as the Stock Price (as defined below) of Company
Post-Closing Common Shares equals or exceeds (x) with respect to the 20% Earn-Out Shares, $15.00 per share (the “20%
Trigger Price”), and (y) with respect to the 10% Earn-Out Shares, $20.00 per share (the “10% Trigger
Price” and, together with the 20% Trigger Price, the “Trigger Price”), in each case, for any 20 Trading
Days within any 30 Trading Day period commencing no earlier than the Closing Date and ending no later than the fifth (5th)
anniversary of the Closing Date (the “Earn-Out End Date”); provided, however, that (i) if the
Earn-Out End Date occurs on a day that is not a Trading Day, then the Earn-Out End Date shall be deemed to occur on the next
following Trading Day, and (ii) if the Company or any of its Affiliates enters into a definitive agreement with respect to a Sale
(as defined below) on or prior to the Earn-Out End Date, then the Earn-Out End Date shall be automatically extended and shall be
deemed to occur on the earlier of (A) the day after such Sale is consummated and (B) the termination of such definitive agreement
with respect to such Sale in accordance with its terms. Any Earn-Out Shares that have not vested in accordance with this Section
2(b) or Section 2(c) on or before the Earn-Out End Date will be immediately forfeited at 11:59 p.m., New York, New York
time on the Earn-Out End Date.

 

    3 

     

    

 

(c)              
In the event of a Sale (as defined below) on or prior to the Earn-Out End Date, any unvested Earn-Out Shares will fully vest and
become free of the restrictions set forth in this Section 2 as of immediately prior to the closing of such Sale. For purposes of
this Agreement, “Sale” means (A) a purchase, sale, exchange, merger, business combination or other transaction or series
of related transactions in which substantially all of the Company Post-Closing Common Shares are, directly or indirectly, converted into
cash, securities or other property or non-cash consideration (other than, in the case of this clause (A), any transaction in which the
holders of Company Post-Closing Common Shares as of immediately prior to the consummation of such transaction continue to own all or substantially
all of the equity securities of the Company (or any successor or parent entity of the Company) immediately following the consummation
of such transaction), (B) a direct or indirect sale, lease, exchange or other transfer (regardless of the form of the transaction) in
one transaction or a series of related transactions of a majority of the Company’s assets, as determined on a consolidated basis,
to a third party or third parties acting as a “group” (as defined in Section 13(d)(3) of the Exchange Act) or (C) any transaction
or series of transactions that results, directly or indirectly, in the shareholders of the Company as of immediately prior to such transactions
holding, in the aggregate, less than fifty percent (50%) of the voting Equity Securities of the Company (or any successor or parent company
of the Company) immediately after the consummation thereof (excluding, for the avoidance of doubt, any Earn-out Shares) (in the case of
each of clause (A), (B) or (C), whether by amalgamation, merger, consolidation, arrangement, tender offer, recapitalization, purchase,
issuance, sale or transfer of Equity Securities or assets or otherwise).

 

(d)               The
MAAC Sponsor agrees that it shall not engage in any Sale Transaction (as defined in the Sponsor Lock-Up Agreement) with respect to
any Earn-Out Shares until such time as the Earn-Out Shares have vested pursuant to Section 2(b) or Section 2(c).
Notwithstanding the foregoing or anything to the contrary herein, (i) the MAAC Sponsor (and, for the avoidance of doubt, any
permitted transferees pursuant to this clause (i)) may transfer all or any of the Earn-Out Shares in any transfer of the type
described in Sections 1(b)(iv)(A) through (C) or (F) of the Sponsor Lock-Up Agreement, provided that, in the case of a
transfer of the type described in clauses (A) through (C), the transferee shall, in addition to any requirements in the Sponsor
Lock-Up Agreement, agree in writing that he, she or it is receiving and holding such Earn-Out Shares subject to the provisions of
this Section 2 and (ii) from and after a transfer pursuant to clause (i) of this sentence, all references to the MAAC Sponsor
in this Section 2 and Section 7 shall include such transferee and shall collectively mean the MAAC Sponsor (to
the extent that it then holds Earn-Out Shares) and each permitted transferee of Earn-Out Shares pursuant to clause (i) of this
sentence (in each case, to the extent he, she or it then holds Earn-Out Shares). Each transferee of Earn-Out Shares pursuant to
clause (i) of the preceding sentence shall be a third party beneficiary of this Section 2 and Section 7.

 

    4 

     

    

 

(e)              
As used herein, “Stock Price” means, on any date on or after the Closing and on or prior to the Earn-Out End
Date, the closing sale price per share of Company Post-Closing Common Shares reported as of 4:00 p.m., New York, New York time on such
date by Bloomberg, or if not available on Bloomberg, as reported by or an authoritative source generally used for such purposes and selected
by the Company, and “Trading Day” means any day on which trading is generally conducted on Nasdaq or any other exchange
on which the Company Post-Closing Common Shares are traded on or after the Closing and on or prior to the Earn-Out End Date. The Earn-out
Shares and the applicable Trigger Price (and all references to Company Post-Closing Common Shares and each of the foregoing in this Agreement)
shall each be adjusted appropriately to reflect the effect of any stock split, reverse stock split, stock dividend (including any dividend
or other distribution of securities convertible into Company Post-Closing Common Shares), reorganization, recapitalization, reclassification,
combination, exchange of shares or other like change with respect to the Company Post-Closing Common Shares (or any other Equity Securities
into which they are adjusted pursuant to this Section 2(e)) at any time prior to the vesting of the Earn-out Shares pursuant to
this Section 2 so as to provide the holders of the Earn-Out Shares with the same economic effect as contemplated by this Section
2 prior to such event and as so adjusted shall, from and after the date of such event, be the Earn-Out Shares and the 20% Trigger
Price or the 10% Trigger Price, as applicable.

 

(f)               
The Company shall use reasonable best efforts to remain listed as a public company on, and for the Earn-Out Shares to be tradable
over, Nasdaq or any other nationally recognized U.S. stock exchange; provided, however, the foregoing shall not limit the
Company or any of its Affiliates from consummating a Sale or entering into a definitive agreement that contemplates a Sale. Subject to
Section 2(c) and the other applicable provisions of this Section 2, upon the consummation of Sale the Company shall have
no further obligations under this Section 2(f).

 

(g)              
At the time that the Earn-Out Shares become vested pursuant to this Section 2, the Company shall remove any legends, stock
transfer restrictions, stop transfer orders or similar restrictions with respect to the Earn-Out Shares related to such vesting or this
Section 2 (other than, for the avoidance of doubt, those that relate to any applicable and then-existing Lock-Up Period (as defined
in the Sponsor Lock-Up Agreement) with respect to such Earn-Out Shares).

 

(h)               For
the avoidance of doubt, (i) the MAAC Sponsor shall retain all of its rights as a stockholder of the Company with respect to the
Earn-Out Shares owned by it during any period of time that such shares are subject to restriction on transfer or sale hereunder,
including the right to vote any such shares and the right to receive dividends and other distributions with respect to such Earn-Out
Shares prior to vesting (provided that dividends and other distributions with respect to Earn-Out Shares that are subject to
vesting and are unvested at the time of such dividend or distribution shall be set aside by the Company and shall only be paid to
such holders upon the vesting of such Earn-Out Shares (and, if any dividends or other distributions with respect to Earn-Out Shares
are set aside and such Earn-Out Shares are subsequently forfeited pursuant to this Section 2, such set aside dividends or
distributions shall become the property of the Company)), (ii) any Earn-Out Shares that vest in accordance with the terms of this Section
2 shall remain subject to any applicable Lock-Up Period set forth in the Sponsor Lock-Up Agreement and (iii) notwithstanding the
expiration of any Lock-Up Period with respect to any Earn-Out Shares, such shares shall remain subject to any applicable
restrictions set forth this Section 2.

 

    5 

     

    

 

(i)                
The MAAC Sponsor intends to make a protective election under Section 83(b) of the Code with respect to the Earn-Out Shares.

 

(j)                
The Parties agree and acknowledge that the Earn-Out Shares are intended to constitute “voting stock” within the meaning
of Section 368(a)(1) of the Code and the Treasury Regulations promulgated thereunder received by MAAC Sponsor in connection with the Merger,
and shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise),
such treatment unless (i) such Party requests that each of Kirkland & Ellis LLP and Davis Polk & Wardwell LLP provides written
confirmation to the effect that such treatment is more likely than not correct, and each such law firm fails to provide such confirmation
prior to the later of (A) thirty (30) days following such request is made and (B) sixty (60) days prior to the date on which the relevant
Tax Return is due (taking into account applicable extensions); provided that the Parties shall provide customary factual representations
to such law firm; provided, further, that, for the avoidance of doubt, the Parties shall not be required to restructure,
or otherwise alter the terms of, the transaction as provided for in this Agreement or the Business Combination Agreement, or (ii) otherwise
required by a final “determination” within the meaning of Section 1313(a) of the Code.

 

3.                 
Sponsor Exchange Ratio. For purposes of the Business Combination Agreement, the term “Sponsor Exchange Ratio”
shall mean: (i) one minus (ii) a number equal to (A) 0.5 multiplied by (B) a fraction equal to (x) the number of MAAC Class
A Shares with respect to which a MAAC Shareholder Redemption has been exercised divided by (y) the total number of MAAC Class A
Shares outstanding as of the date hereof; provided that the number referenced in the foregoing clause (ii) shall not in any event
be greater than 0.25.

 

4.                 
Working Capital Loans; Related Party Agreements.

 

(a)              
With respect to any loan of funds made by the MAAC Sponsor or an Affiliate of the MAAC Sponsor or any of MAAC’s officers
or directors (each, a “Lender”) to MAAC or any of its Subsidiaries, in each case, prior to the Closing (a “Working
Capital Loan”) that is or may be convertible into warrants or other securities (derivative or otherwise) of MAAC or the Company,
MAAC, the MAAC Sponsor and the Insiders hereby agrees, and shall take such reasonably necessary or appropriate actions within its power
so as to ensure, that each and any Working Capital Loan shall be repaid solely in cash, and that no Working Capital Loan will be converted
into warrants or other securities (derivative or otherwise) of MAAC or the Company, notwithstanding any applicable provisions of the Insider
Letter, the Warrant Agreement, the MAAC Registration Rights Agreement or any other Contract.

 

    6 

     

    

 

(b)              
 MAAC and the MAAC Sponsor agree that, notwithstanding anything to the contrary in any such agreement, (i) each of the agreements
set forth on Schedule A attached hereto shall be automatically terminated and of no further force and effect (including any
provisions of any such agreement that, by its terms, survive such termination), effective as of, and subject to and conditioned upon the
occurrence of, the Closing and (ii) upon such termination, MAAC shall not have any further Liabilities under each such agreement.

 

5.                 
MAAC Registration Rights Agreement. Subject to, and conditioned upon the occurrence and effective as of the Effective Time,
MAAC, the MAAC Sponsor and each of the other Shareholders who are party to the MAAC Registration Rights Agreement agree that the MAAC
Registration Rights Agreement is hereby terminated in its entirety, and shall be of no further force or effect from and after such time.

 

6.                 
Anti-Dilution Adjustment Waiver. Subject to, and conditioned upon the occurrence of and effective as of immediately prior
to the Effective Time, the MAAC Sponsor, which is the holder of at least a majority of the outstanding MAAC Class B Shares as of the date
hereof, hereby waives on behalf of the holders of all MAAC Class B Shares, pursuant to and in compliance with the provisions of the Amended
and Restated Certificate of Incorporation of MAAC (the “MAAC Charter”), any adjustment to the conversion ratio set
forth in Article Eighth of the MAAC Charter, and any rights to other anti-dilution protections with respect to the MAAC Class B Shares,
that may result from the PIPE Financing and/or the consummation of the Transactions.

 

7.                 
Registration Rights.

 

(a)              
Capitalized terms used in this Section 7 but not otherwise defined herein shall have the meanings ascribed to them in the
Registration Rights Agreement (as in effect as of the date hereof); provided that, for purposes of Section 7, (i) the term
 “Registrable Securities” shall be deemed to include the Common Shares (including any Common Shares underlying any other securities
of the Company or into which other securities of the Company are convertible into, exercisable or exchangeable for) held by or on behalf
of the Shareholders as of immediately following the Effective Time and (ii) the term “Investor” shall be deemed to include
the MAAC Sponsor.

 

(b)               The
Company shall file within thirty (30) days of the consummation of the Go Public Transaction, and use commercially reasonable efforts
to cause to be declared effective as soon as practicable thereafter, a Resale S-1 Shelf or, if the Company is eligible to use a
Resale S-3 Shelf, in each case, covering the resale of all the Registrable Securities (determined as of two business days prior to
such filing) and any other Common Shares or other securities of the Company issued in connection with the Go Public Transaction
(including any Common Shares underlying any other securities of the Company or into which other securities of the Company are
convertible into, exercisable or exchangeable for) the transfer or sale of which has not been registered under the Securities Act; provided,
that the Company and the Shareholders acknowledge and agree that the sale of any Registrable Securities registered under such Resale
Shelf may be subject to restrictions imposed by the Lock-Up Agreements and/or applicable securities laws. Such Resale Shelf shall
provide for the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally
available to, and requested by, the MAAC Sponsor and any other Investor named therein. The MAAC Sponsor shall be entitled to the
benefits of Section 4 and the first, second and third sentences of Section 1(f)(ii), mutatis mutandis, under the
Registration Rights Agreement with respect to its Common Shares or other securities of the Company and it shall not be subject to
any “cutback” or other restriction in connection with the inclusion of its Common Shares or other securities in any
Resale Shelf.

 

    7 

     

    

 

(c)              
The MAAC Sponsor will be offered an opportunity to participate in (x) an offering and/or sale of Common Shares by any holder that
is conducted as a block trade or underwritten basis (whether firm commitment or otherwise) without substantial marketing efforts prior
to pricing, including, without limitation, a same day trade, overnight trade or similar transaction or (y) an “at the market”
or similar registered offering of the Covered Securities through a broker, sales agent or distribution agent, whether as agent or principal.
The rights of the MAAC Sponsor set forth in this Section 7(c) shall be substantially the same as those investors who are party
to the Registration Rights Agreement.

 

8.                 
Other Covenants and Agreements.

 

(a)               Each
Shareholder shall not, and each Shareholder shall cause its controlled Affiliates and its and their respective officers and
directors not to, and shall use reasonable best efforts to cause its other Representatives not to, at or at any time prior to the
Effective Time, issue any press releases or make any public announcements with respect to this Agreement, the Business Combination
Agreement or the transactions contemplated hereby or thereby that contain any information that is not, at the applicable time,
already publicly available (other than as a result of disclosure by the Shareholder in violation of any applicable confidentiality
obligations) without the prior written consent of the Company and MAAC, provided, however, that the Shareholder and
its Representatives may issue or make, as applicable, any such press release, public announcement or other communication to the
extent such press release, public announcement or other communication is required by applicable Law or applicable rule of a stock
exchange on which its or any of its Affiliates’ securities are listed, in which case the Shareholder or its applicable
Affiliates shall, to the extent reasonably practicable and unless and to the extent prohibited by such applicable Law, reasonably
consult with the Company and MAAC in connection therewith and provide the Company and MAAC with an opportunity to review and comment
on such press release, public announcement or communication and shall consider any such comments in good faith. Notwithstanding
anything to the contrary in this Section 8(a) or otherwise in this Agreement, each Shareholder and its Representatives may
provide general information about the subject matter of this Agreement, the Business Combination Agreement and the transactions
contemplated hereby and thereby (1) to their respective affiliates, their and their affiliates’ respective directors,
officers, employees, partners, members, agents, attorneys and consultants, financial and other advisors, (2) to the extent required
by any federal, state, national, foreign or other regulatory or self-regulatory authority having jurisdiction over the Shareholder
or its Representatives, (3) to any Person if necessary to effect compliance with any law, rule, regulation, investigation, audit,
request or order of a Governmental Entity of competent jurisdiction that is applicable to the Shareholder or its Representatives,
including in response to any subpoena or other legal process, audit or examinations or (4) to any direct or indirect former, current
or prospective investor or in connection with normal fund raising or related marketing or informational or reporting activities (so
long as, in the case of this clause (4), the recipients of such information are subject to customary confidentiality obligations
prior to the receipt of such information); provided further that in the case of the foregoing clause (2) and (3), each Shareholder
or its Representatives promptly notifies the Company of such disclosure to the extent the Shareholder or its Representatives are
legally permitted to give such notice and it is reasonably practicable; provided further that no such notice shall be required where
disclosure is made (x) in response to and required by a general request by a regulatory or self-regulatory authority of competent
jurisdiction or (y) in connection with and required by a routine audit or examination by a bank examiner or auditor and such audit
or examination does not reference the Company, this Agreement or the Business Combination Agreement.

 

    8 

     

    

 

(b)              
If applicable, prior to the Effective Time, each Shareholder hereby agrees to as promptly as practicable execute and deliver all
additional agreements, documents or instruments, take, or cause to be taken, all actions and provide, or cause to be provided, all additional
information or other materials as may be necessary or reasonably advisable, in each case, as mutually reasonably determined and agreed
to by MAAC and the Company (such determination and agreement not to be unreasonably withheld, conditioned or delayed by either MAAC or
the Company), in connection with, or otherwise in furtherance of, the transactions and the other covenants and agreements contemplated
by the Business Combination Agreement or this Agreement (provided, however, that in no event shall any Shareholder be obligated
to take, approve or consent to any action that would result in any adverse economic or other material change to the Business Combination
Agreement, this Agreement or any other Ancillary Document to which he, she or it is or will be a party). If applicable, from and after
the Effective Time, MAAC Sponsor and the Company each hereby agrees to as promptly as practicable execute and deliver execute and deliver
all additional agreements, documents or instruments, take, or cause to be taken, all actions and provide, or cause to be provided, all
additional information or other materials as may be reasonably necessary to effectuate the purpose of the covenants and agreements of
this Agreement that survive the Effective Time. Notwithstanding the foregoing, no Shareholder or the Company shall be required to provide
any information which is, based on the advice of outside counsel, subject to legal privilege.

 

(c)               Without
limiting Section 8(b), the MAAC Sponsor and the Company shall each (i) make any appropriate filings pursuant to the HSR Act
with respect to the Company Post-Closing Common Shares to be received by the MAAC Sponsor pursuant to the terms of the Business
Combination Agreement as promptly as reasonably practicable (and in any event within ten (10) Business Days) following the date of
this Agreement, (ii) use reasonable best efforts to obtain any other approvals of any Governmental Entity as may be required to be
obtained by the MAAC Sponsor or the Company in connection with the receipt by the MAAC Sponsor of the Company Post-Closing Common
Shares to be received by the MAAC Sponsor pursuant to the terms of the Business Combination Agreement and (iii) respond as promptly
as reasonably practicable to any requests by any Governmental Entity for additional information and documentary material that may be
requested pursuant to the HSR Act or in connection with such other required approvals of any Governmental Entity described in clause
(ii). The MAAC Sponsor and the Company shall each pay fifty percent (50%) of the HSR Act filing fee. Without limiting the foregoing,
the MAAC Sponsor and its applicable Affiliates and the Company and its applicable Affiliates shall not (A) extend any waiting
period, review period or comparable period under the HSR Act or in connection with such other required approvals of any Governmental
Entity, (B) request early termination of any waiting period, review period or comparable period under the HSR Act without the prior
written consent of the MAAC Sponsor (in the case of the Company or any of its applicable Affiliates) or the Company (in the case of
the MAAC Sponsor or any of its applicable Affiliates) or (C) enter into any agreement with any Governmental Entity not to consummate
the transactions contemplated by the Business Combination Agreement except with the prior written consent of the Company and MAAC
(in the case of MAAC Sponsor or any of its applicable Affiliates) or MAAC Sponsor (in the case of the Company or any of its
applicable Affiliates). The MAAC Sponsor shall promptly inform the Company and MAAC of any communication received by the MAAC
Sponsor from any Governmental Entity relating to the matters contemplated by this Section 8(c), and the Company shall
promptly inform the MAAC Sponsor and MAAC of any communication received by any Group Company from any Governmental Entity relating
to the matters contemplated by this Section 8(c). The MAAC Sponsor shall give the Company and its counsel, and MAAC and its
counsel, a reasonable opportunity to review in advance, and consider in good faith the views thereof in connection with, any
proposed written communication to any Governmental Entity relating to the matters contemplated by this Section 8(c), and the
Company shall give MAAC Sponsor and its counsel and MAAC and its counsel a reasonable opportunity to review in advance, and consider
in good faith the views thereof in connection with, any proposed written communication to any Governmental Entity relating to the
matters contemplated by this Section 8(c). The MAAC Sponsor and the Company each agrees not to, and to cause its
Representatives not to, participate in any substantive meeting or discussion, either in person or by telephone with any Governmental
Entity in connection with the matters contemplated by this Section 8(c) unless it consults with the Company and MAAC (in the
case of the MAAC Sponsor or its Representatives) or the MAAC Sponsor and MAAC (in the case of the Company or its Representatives) in
advance and, to the extent not prohibited by such Governmental Entity, gives the Company and MAAC (in the case of the MAAC Sponsor
or its Representatives) or the MAAC Sponsor and MAAC (in the case of the Company or its Representatives) the opportunity to attend
and participate in such meeting or discussion.

 

    9 

     

    

 

(d)              
Each Shareholder acknowledges and agrees that MAAC and the Company are entering into the Business Combination Agreement in reliance
upon such Shareholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable,
the applicable agreements, covenants and obligations contained in this Agreement and, but for each Shareholder entering into this Agreement
and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the applicable agreements, covenants and obligations
contained in this Agreement, MAAC and the Company would not have entered into or agreed to consummate the transactions contemplated by
the Business Combination Agreement.

 

9.                 
Shareholder Representations and Warranties. Each Shareholder represents and warrants, as of the date hereof, solely with
respect to himself, herself or itself, and not on behalf of any other Shareholder, to the Company and MAAC as follows:

 

(a)              
If the Shareholder is not an individual, the Shareholder is a corporation, limited liability company or other applicable business
entity duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each
case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction
of formation or organization (as applicable).

 

    10 

     

    

 

(b)               The
Shareholder (if not an individual) has the requisite corporate, limited liability company or other similar power and authority and,
if the Shareholder is an individual, legal capacity to execute and deliver this Agreement, to perform his, her or its covenants,
agreements and obligations hereunder (including, for the avoidance of doubt, those covenants, agreements and obligations hereunder
that relate to the provisions of the Business Combination Agreement), and to consummate the transactions contemplated hereby. The
execution and delivery of this Agreement has been duly authorized by all necessary corporate or other action on the part of the
Shareholder. This Agreement has been duly and validly executed and delivered by the Shareholder and constitutes a valid, legal and
binding agreement of the Shareholder (assuming that this Agreement is duly authorized, executed and delivered by the other parties
hereto), enforceable against the Shareholder in accordance with its terms (subject to applicable bankruptcy, insolvency,
reorganization, moratorium or other Laws affecting generally the enforcement of creditors’ rights and subject to general
principles of equity).

 

(c)              
No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity is required on the
part of the Shareholder with respect to the Shareholder’s execution, delivery or performance of his, her or its covenants, agreements
or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and obligations under this Agreement
that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions contemplated hereby, except
for (A) compliance with and filings under the HSR Act, if applicable, or under any applicable Foreign and Domestic Approval Laws, (B)
any filings with the SEC related to his, her or its ownership of Equity Securities of MAAC or Company Post-Closing Common Shares or the
transactions contemplated by the Business Combination Agreement, this Agreement or any other Ancillary Documents to which he, she or it
is a party, or (C) any other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which
would not reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his,
her or its covenants, agreements or obligations hereunder in any material respect.

 

(d)              
None of the execution or delivery of this Agreement by the Shareholder, the performance by the Shareholder of any of his, her or
its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and
obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions
contemplated hereby will, directly or indirectly (with or without due notice or lapse of time or both) (i) if the Shareholder is not an
individual, result in any breach of any provision of the Shareholder’s Governing Documents, (ii) result in a violation or breach
of, or constitute a default or give rise to any right of termination, Consent, cancellation, amendment, modification, suspension, revocation
or acceleration under, any of the terms, conditions or provisions of any Contract to which the Shareholder is a party, (iii) violate,
or constitute a breach under, any Order or applicable Law to which the Shareholder or any of his, her or its properties or assets are
bound or (iv) other than the restrictions contemplated by this Agreement, the Business Combination Agreement or any other Ancillary Document,
result in the creation of any Lien upon the Subject Company Securities (other than as expressly provided under this Agreement), except,
in the case of any of clauses (ii) and (iii) above, as would not reasonably be expected to adversely affect the ability
of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any
material respect.

 

    11 

     

    

 

(e)              
 The Shareholder is, as of the date hereof, the record and beneficial owner of the Subject Company Securities as set forth on Exhibit
A hereto. The Shareholder has the sole right to vote (and provide consent in respect of, as applicable) the Subject Company Securities
set forth on Exhibit A hereto as of the date hereof. Except for this Agreement, the Business Combination Agreement, the other Ancillary
Documents to which he, she or it is or will be a party, the Affected Agreements and the Governing Documents of MAAC, the Shareholder is
not party to or bound by (i) any option, warrant, purchase right or other Contract that would reasonably be expected (either alone or
in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to require
the Shareholder to Transfer any of the Subject Company Securities or (ii) any voting trust, proxy or other Contract with respect to the
voting or Transfer of any of the Subject Company Securities, in the case of either clause (i) or (ii), that would reasonably be expected
to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements
or obligations hereunder in any material respect.

 

(f)               
There is no Proceeding pending or, to the Shareholder’s knowledge, threatened against or involving the Shareholder or any
of his, her or its Affiliates that, if adversely decided or resolved, would reasonably be expected to adversely affect the ability of
the Shareholder to perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement in any material
respect.

 

(g)              
The Shareholder, on his, her or its own behalf and on behalf of his, her or its Representatives, acknowledges, represents, warrants
and agrees that he, she or it has conducted his, her or its own independent review and analysis of, and, based thereon, has formed an
independent judgment concerning, the business, assets, condition, operations and prospects of, the Company and the transactions contemplated
by this Agreement, the Business Combination Agreement and the other applicable Ancillary Documents to which he, she or it is or will be
a party as he, she or it and his, her or its Representatives have deemed necessary to enable him, her or it to make an informed decision
with respect to the execution, delivery and performance of this Agreement or the other Ancillary Documents to which he, she or it is or
will be a party and the transactions contemplated hereby and thereby.

 

(h)              
In entering into this Agreement and the other Ancillary Documents to which he, she or it is or will be a party, the Shareholder
has relied solely on his, her or its own investigation and analysis and the representations and warranties expressly set forth in the
Ancillary Documents to which he, she or it is or will be a party and no other representations or warranties of MAAC, the Company or any
other Person, either express or implied, and the Shareholder, on his, her or its own behalf and on behalf of his, her or its Representatives,
acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in this Agreement
or in the other Ancillary Documents to which he, she or it is or will be a party, none of MAAC, the Company or any other Person makes
or has made any representation or warranty, either express or implied, to the Shareholder in connection with or related to this Agreement,
the Business Combination Agreement or the other Ancillary Documents or the transactions contemplated hereby or thereby.

 

10.              Company
and MAAC Acknowledgement. In entering into this Agreement, the Business Combination Agreement and the other Ancillary Documents
to it is or will be a party, each of the Company and MAAC have not relied on any representations or warranties of the Shareholder,
either express or implied, except for the representations and warranties of the Shareholder expressly set forth in this Agreement or
in the other Ancillary Documents to which he, she or it is or will be a party and to which MAAC or the Company, as applicable, is or
will be a party.

 

    12 

     

    

 

11.             
Transfer of Subject Company Securities. From and after the date hereof and until the earlier of (A) the termination of this
Agreement in accordance with its terms and (B) the Effective Time, each Shareholder agrees not to (a) Transfer any of the Subject Company
Securities, (b) enter into (i) any option, warrant, purchase right, or other Contract that would reasonably be expected (either alone
or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to
require the Shareholder to Transfer the Subject Company Securities or (ii) any voting trust, proxy or other Contract with respect to the
voting or Transfer of the Subject Company Securities, or (c) take any actions in furtherance of any of the matters described in the foregoing
clauses (a) or (b), unless, in the case of clauses (a) through (c), the Shareholder causes any transferee of any such Transfer to enter
into a written agreement in form and substance reasonably satisfactory to MAAC and the Company agreeing to be bound by this Agreement
(which will include, for the avoidance of doubt, all of the covenants, agreements and obligations of the Shareholder hereunder and the
making of all the representations and warranties of the Shareholder set forth in Section 9 with respect to such transferee and
his, her or its Subject Company Securities received upon such Transfer, as applicable) prior and as a condition to the occurrence of such
Transfer; provided that, if the Shareholder is not an individual, a Transfer of securities in the Shareholder by an equityholder
of the Shareholder shall not require the transferee to enter into such written agreement so long as (x) following such Transfer, the Shareholder
continues to hold the Subject Company Securities and to have the exclusive right to vote and to take all other actions related to the
ownership of the Subject Company Securities without restriction and (y) such Transfer would otherwise be permitted under the Shareholders
Agreement. For purposes of this Agreement, “Transfer” means any direct or indirect sale, transfer, assignment, pledge,
mortgage, exchange, hypothecation, grant of a security interest in or disposition or encumbrance of an interest (whether with or without
consideration, whether voluntarily or involuntarily or by operation of law or otherwise).

 

12.              Termination.
This Agreement shall automatically terminate, without any notice or other action by any Party, and be void ab initio upon the
termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in
the immediately preceding sentence, none of the Parties shall have any further obligations or Liabilities under, or with respect to,
this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i) the termination of this Agreement
shall not affect any Liability on the part of any Party for a Willful Breach of any covenant or agreement set forth in this
Agreement prior to such termination or Fraud, (ii) Section 10, this Section 12 and the representations and warranties
set forth in Sections 9(g) and (h) shall each survive any termination of this Agreement, and (iii) Sections 13
through 21 shall survive any termination of this Agreement. For purposes of this Section 12, (x) “Willful
Breach” means a material breach of this Agreement that is a consequence of an act or a failure to act by the breaching
Party with the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, constitute or
result in a breach of this Agreement and (y) “Fraud” means an act or omission by a Party, and requires: (A) a
false or incorrect representation or warranty expressly made by such Party in this Agreement, (B) with actual knowledge (as opposed
to constructive, imputed or implied knowledge) by the Party making such representation or warranty that such representation or
warranty expressly set forth in this Agreement is false or incorrect, (C) an intention to deceive another Party, to induce him, her
or it to enter into this Agreement, (D) another Party, in justifiable or reasonable reliance upon such false or incorrect
representation or warranty expressly set forth in this Agreement, entering into this Agreement, and (E) another Party suffering
damage by reason of such reliance. For the avoidance of doubt, “Fraud” does not include any claim for equitable fraud,
promissory fraud, unfair dealings fraud or any torts (including a claim for fraud or alleged fraud) based on negligence or
recklessness.

 

    13 

     

    

 

13.             
Fiduciary Duties. Notwithstanding anything in this Agreement to the contrary, (a) the Shareholder makes no agreement
or understanding herein in any capacity other than in such Shareholder’s capacity as a record holder and beneficial owner of the
Subject Company Securities and, (i.e., if such Shareholder is an individual, not in such Shareholder’s capacity as a director, officer
or employee of MAAC), and (b) nothing herein will be construed to limit or affect any action or inaction by such Shareholder if such Shareholder
is an individual, or, if such Shareholder is not an individual, any representative of such Shareholder serving as a member of the board
of directors of MAAC or as an officer, employee or fiduciary of MAAC, in each case, acting in such person’s capacity as a director,
officer, employee or fiduciary of MAAC.

 

14.             
Notices. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given
(and shall be deemed to have been duly given) by delivery in person, by e-mail (having obtained electronic delivery confirmation thereof
(i.e., an electronic record of the sender that the email was sent to the intended recipient thereof without an “error” or
similar message that such email was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return
receipt requested) (upon receipt thereof) to the other Parties as follows:

	 
	If to MAAC or the MAAC Sponsor, to:
	 
	 	c/o Patient Square Capital
	 	724 Oak Grove Ave, Suite 130
	 	Menlo Park, California 94025
	 	Attention:	Maria Walker
	 	Email:	maria@patientsquarecapital.com
	 
	with a copy (which shall not constitute notice) to:
	 
	 	Kirkland & Ellis LLP
	 	601 Lexington Avenue
	 	New York, NY 10022
	 	Attention:	 Michael Weisser, P.C.; Ryan Brissette; Sharon Freiman
	 
	Email:
	michael.weisser@kirkland.com; ryan.brissette@kirkland.com;

                                                                     

	 	 	sharon.freiman@kirkland.com

 

    14 

     

    

 

	If to the Company, to:
	 
	 	Roivant Sciences Ltd.
	 	Suite 1, 3rd Floor
	 	11-12 St. James’s Square
	 	London SW1Y 4LB
	 	United Kingdom
	 	Attention:	Matthew Gline
	 	E-mail:	matthew.gline@roivant.com; legalnotices@roivant.com
	 
	with a copy (which shall not constitute notice) to:
	 
	 	Roivant Sciences, Inc.
	 	151 West 42nd Street, 15th Floor
	 	New York, NY 10036
	 	Attention:	General Counsel
	 	Email:	jo.chen@roivant.com
	 
	with a copy (which shall not constitute notice) to:
	 
	 	Davis Polk & Wardwell LLP
	 	450 Lexington Avenue
	 	New York, NY 10017
	 	Attention:	Derek Dostal; Lee Hochbaum; Brian Wolfe
	 	Email:	derek.dostal@davispolk.com; lee.hochbaum@davispolk.com;
	 	 	brian.wolfe@davispolk.com
	 
	if to a Shareholder other than the MAAC Sponsor, to the address on the Shareholder’s signature page hereto;

 

or to such other address as the Party to whom notice is given may have
previously furnished to the others in writing in the manner set forth above.

 

15.             
Entire Agreement. This Agreement, the Business Combination Agreement and documents referred to herein and therein (including
the Ancillary Documents) constitute the entire agreement of the Parties with respect to the subject matter of this Agreement, and supersede
all prior agreements and undertakings, both written and oral, among the Parties with respect to the subject matter of this Agreement,
except as otherwise expressly provided in this Agreement. In the event and to the extent that there shall be a conflict between the provisions
of this Agreement and the provisions of any Affected Agreement, this Agreement shall control with respect to the subject matter thereof.

 

16.              Amendments
and Waivers; Assignment. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is
in writing and signed by the Shareholders, the Company and MAAC. Notwithstanding the foregoing, no failure or delay by any Party in
exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other
or further exercise of any other right hereunder. Subject to Section 2(d), neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assignable by a Shareholder or the Company without MAAC’s prior written consent
(to be withheld or given in its sole discretion) or by MAAC without the Company’s prior written consent (to be withheld or
given in its sole discretion). Any attempted assignment of this Agreement not in accordance with the terms of this Section 16
shall be null and void ab initio.

 

    15 

     

    

 

17.             
Fees and Expenses. Except, in the case of MAAC and the Company, as otherwise expressly set forth in the Business Combination
Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including the fees
and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses; provided,
that, any such reasonable and documented fees and expenses incurred by the Shareholders in connection with this Agreement and the transactions
contemplated hereby on or prior to the Closing shall be deemed to be fees and expenses of MAAC.

 

18.             
No Third Party Beneficiaries. Except as set forth in Section 2(d), this Agreement shall be for the sole benefit of
the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other
than the Parties and their respective successors and permitted assigns, any legal or equitable right, benefit or remedy of any nature
whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to, or shall be deemed to, create a
joint venture.

 

19.             
Miscellaneous. Sections 8.5 (Governing Law), 8.7 (Construction; Interpretation), 8.10 (Severability),
8.11 (Counterparts; Electronic Signatures), 8.15 (Waiver of Jury Trial), 8.16 (Submission to Jurisdiction) and 8.17
(Remedies) of the Business Combination Agreement are incorporated herein by reference and shall apply to this Agreement, mutatis mutandis.

 

20.             
No Ownership Interest. Nothing contained in this Agreement will be deemed to vest in the Company, any Company Non-Party
Affiliate, or any MAAC Non-Party Affiliate any direct or indirect ownership or incidents of ownership of or with respect to the Subject
Company Securities. All rights, ownership and economic benefits of and relating to the Subject Company Securities shall remain vested
in and belong to each Shareholder, and the Company and MAAC (and each other Company Non-Party Affiliate and MAAC Non-Party Affiliate)
shall have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of
Company or exercise any power or authority to direct any Shareholder in the voting of any of the Subject Company Securities, except as
otherwise expressly provided herein with respect to the Subject Company Securities. Except as otherwise set forth in Section 1, no Shareholder
shall not be restricted from voting in favor of, against or abstaining with respect to any other matters presented to the stockholders
of MAAC.

 

21.             
Spouses and Community Property Matters. Each Shareholder’s spouse (if applicable) hereby represents, warrants and
covenants to MAAC and the Company that such spouse shall not assert or enforce, and does hereby waive, any rights granted under any community
property statue with respect to the Subject Company Securities that would adversely affect (x) the covenants made by the applicable Shareholder
pursuant to this Agreement or (y) the transactions contemplated by the Business Combination Agreement and the Ancillary Documents.

 

    16 

     

    

 

22.              No
Recourse. Except for claims pursuant to the Business Combination Agreement or any Ancillary Document by any party(ies) thereto
against any other party(ies) on the terms and subject to the conditions therein, each Party agrees that (a) this Agreement may only
be enforced against, and any action for breach of this Agreement may only be made against, the Parties, and no claims of any nature
whatsoever arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions
contemplated hereby shall be asserted against any Person that is not a Party, and (b) without limiting the generality of the
foregoing, no Person that is not a Party shall have any Liability arising out of or relating to this Agreement, the negotiation
hereof or its subject matter, or the transactions contemplated hereby, including with respect to any claim (whether in tort,
contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made
in connection herewith, except as expressly provided herein. Notwithstanding anything to the contrary in this Agreement, (i) in no
event shall any Shareholder have any obligations or Liabilities related to or arising out of the covenants, agreements, obligations,
representations or warranties of any other Shareholder under this Agreement (including related to or arising out of the breach of
any such covenant, agreement, obligation, representation or warranty by any other Shareholder), and (ii) in no event shall MAAC have
any obligations or Liabilities related to or arising out of the covenants, agreements, obligations, representations or warrants of
any Shareholder under this Agreement (including related to or arising out of any breach of any such covenant, agreement, obligation,
representation or warranty by any such Shareholder).

 

23.             
Non-Survival. The representations, warranties, agreements and covenants in this Agreement shall terminate at the Effective
Time, except for those covenants and agreements in this Agreement that, by their terms, expressly contemplate performance or survival
after the Effective Time, which covenants and agreements shall so survive the Effective Time in accordance with their terms; provided
that the foregoing shall not limit any Party’s rights in the event of another Party’s Willful Breach of any agreement
and covenant set forth in Section 4(a) or Section 11 prior to the Effective Time.

 

[Signature page(s) follow(s).]

 

    17 

     

    

 

IN WITNESS WHEREOF, the Parties
have executed and delivered this Agreement as of the date first above written.

 

	 	MONTES ARCHIMEDES ACQUISITION CORP.
	 	 
	 	By:	/s/ Maria C. Walker
	 	Name: 	Maria C. Walker
	 	Title:	Chief Financial Officer

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties
have executed and delivered this Agreement as of the date first above written.

 

	 	ROIVANT SCIENCES LTD.
	 	 
	 	By:	/s/ Marianne Romeo
	 	Name: 	Marianne Romeo
	 	Title:	Head, Global Transactions & Risk Management

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties
have executed and delivered this Agreement as of the date first above written.

 

	 	PATIENT SQUARE CAPITAL LLC
	 	 
	 	By:	/s/ Maria C. Walker
	 	Name: 	Maria C. Walker
	 	Title:	Chief Financial Officer

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties
have executed and delivered this Agreement as of the date first above written.

 

	 	 	INSIDERS
	 	 	 
	 	 	 
	 	By:  	  /s/ James C. Momtazee
	 	Name:	James C. Momtazee
	 	 	 
	 	 	 
	 	By: 	  /s/ George Barrett
	 	Name:	George Barrett
	 	 	 
	 	 	 
	 	By:	  /s/ Maria C. Walker
	 	Name:	Maria C. Walker
	 	 	 
	 	 	 
	 	By: 	  /s/ Steve Oesterle
	 	Name:	Steve Oesterle

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

EXHIBIT A 

 

[Redacted]

 

[Exhibit A to Sponsor Support Agreement]

 

     

     

    

 

SCHEDULE A

 

		1.	The letter, dated as of October 6, 2020, regarding “administrative support agreement” by and between MAAC and the MAAC
Sponsor.

 

		2.	The Securities Subscription Agreement, dated as of July 23, 2020, by and between MAAC and the MAAC Sponsor.

 

[Schedule A to Sponsor Support Agreement]Exhibit 10.2

 

FINAL FORM

 

 

SUBSCRIPTION AGREEMENT

 

Montes Archimedes Acquisition
Corp.

724 Oak Grove, Suite 130

Menlo Park, CA 94025

 

Ladies and Gentlemen:

 

This Subscription Agreement
(this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and
among Montes Archimedes Acquisition Corp., a Delaware corporation (“SPAC”),
the undersigned subscriber (the “Investor”) and, solely for the purposes of Sections 6, 8 and 11, Roivant Sciences
Ltd., a Bermuda exempted limited company (the “Company”), in connection with the Business Combination Agreement, dated
as of the date hereof (as may be amended, supplemented or otherwise modified from time to time, the “BCA”), by and
among SPAC, the Company, Rhine Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of the Company (“Merger
Sub”) and the other parties thereto, pursuant to which, among other things, Merger Sub will merge with and into SPAC (the “Merger”),
with SPAC as the surviving company in the Merger and, after giving effect to the Merger, will become a subsidiary of the Company, on the
terms and subject to the conditions therein (the transactions contemplated by the BCA, including the Merger, the “Transaction”).

 

In connection with the Transaction,
SPAC is seeking commitments from interested investors to purchase, contingent upon, and immediately prior to the closing of the Transaction,
shares of SPAC’s Class A common stock, par value $0.0001 per share (the “Shares”), in a private placement for
a purchase price of $10.00 per share (the “Per Share Purchase Price”). On or about the date of this Subscription Agreement,
SPAC is entering into subscription agreements (the “Other Subscription Agreements” and, together with the Subscription
Agreement, the “Subscription Agreements”) substantially similar to this Subscription Agreement with certain other investors
(the “Other Investors” and, together with the Investor, the “Investors”), pursuant to which the
Investors, severally and not jointly, have agreed to purchase on the closing date of the Transaction,
inclusive of the Shares subscribed for by the Investor, an aggregate amount of up to 20,000,000 Shares, at the Per Share Purchase Price.
The aggregate purchase price to be paid by the Investor for the subscribed Shares (as set forth on the signature page hereto) is referred
to herein as the “Subscription Amount.” Pursuant to the BCA, on the Closing Date (as defined herein), the Shares
so purchased will be exchanged for shares of the Company on a one-for-one basis, as described more fully in the BCA. For the avoidance
of doubt, with respect to any obligations existing in this Subscription Agreement, following consummation of the Transaction, (i) the
Company shall be the public issuer and (ii) the term “Shares” as defined above shall refer to the as-converted shares in the
Company. Notwithstanding anything to the contrary herein, nothing in this Subscription Agreement shall be interpreted to limit the consummation
of the Transaction in accordance with the terms of the BCA.

 

In connection therewith, and
in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the conditions, set forth herein,
and intending to be legally bound hereby, each of the Investor, the Company and SPAC acknowledges and agrees as follows:

 

1.             Subscription.
The Investor hereby irrevocably subscribes for and agrees to purchase from SPAC the number of Shares set forth on the signature page
of this Subscription Agreement on the terms and subject to the conditions provided for herein.

 

2.             Closing.
The closing of the sale of the Shares contemplated hereby (the “Closing”)
is contingent upon the substantially concurrent consummation of the Transaction. The Closing shall occur on the date of, and substantially
concurrently with and conditioned upon the effectiveness of, the Transaction. Upon (a) satisfaction or waiver of the conditions set forth
in Section 3 below and (b) delivery of written notice from (or on behalf of) SPAC to the Investor (the “Closing
Notice”), that SPAC reasonably expects all conditions to the closing of the Transaction to be satisfied or waived on
a date that is not less than five (5) business days from the date on which the Closing Notice is delivered to the Investor, the Investor
shall deliver to SPAC (i) at least one (1) business day prior to the closing date specified in the Closing Notice (the “Closing
Date”), the Subscription Amount by wire transfer of United States dollars in immediately available funds to the account(s)
specified by SPAC in the Closing Notice to be held in escrow until the Closing, or (ii) on the Closing Date, the Subscription Amount
to an account specified by SPAC otherwise mutually agreed by the Investor and SPAC due to legal reasons that apply to such Investor (the “Alternative
Settlement Procedures”) by wire transfer of United States dollars in immediately available funds. The Investor shall also deliver
to SPAC, at least one (1) business day prior to the Closing Date, any other information that is reasonably requested in the Closing Notice
in order for SPAC to issue the Shares to the Investor in accordance with the Subscription Agreement, including, without limitation, the
legal name of the person in whose name such Shares are to be issued and a duly executed Internal Revenue Service Form W-9 or W-8, as
applicable. On the Closing Date, SPAC shall (1) issue a number of Shares to the Investor set forth on the signature page to this Subscription
Agreement and subsequently cause such Shares to be registered in book entry form in the name of the Investor (or its nominee in accordance
with its delivery instructions) on SPAC’s share register, free and clear of any liens or other restrictions (other than those arising
under this Subscription Agreement or applicable securities laws), and (2) provide evidence from the Company’s transfer agent of
such issuance on and as of the Closing Date. If the Closing does not occur within three (3) business days following the Closing
Date specified in the Closing Notice, SPAC shall promptly (but not later than one (1) business day thereafter) return the Subscription
Amount in full to the Investor, in immediately available funds to the account specified by the Investor in writing, and any book entries
for the Shares shall be deemed cancelled. For purposes of this Subscription Agreement, “business
day” shall mean a day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized
or required by law to close.

 

     

     

    

 

3.             Closing
Conditions.

 

(a)            The obligation of the parties hereto to consummate the purchase and sale of the Shares pursuant to this Subscription Agreement
is subject to the following conditions:

 

(i)                
no applicable governmental authority shall have enacted, issued, promulgated, enforced or entered any injunction, judgment,
order, law, rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making the
consummation of the transactions contemplated hereby illegal or otherwise enjoining, restraining or prohibiting consummation of the transactions
contemplated hereby; and

 

(ii)               
all conditions precedent to the closing of the Transaction under the BCA shall have been satisfied (as determined by the
parties to the BCA and other than those conditions under the BCA which, by their nature, are to be fulfilled at the closing of the Transaction,
including to the extent that any such condition is dependent upon the consummation of the purchase and sale of the Shares pursuant to
this Subscription Agreement or Other Subscription Agreements) or waived and the closing of the Transaction shall be scheduled to occur
concurrently with or on the same date as the Closing Date.

 

(b)            The
obligation of SPAC to consummate the issuance and sale of the Shares pursuant to this Subscription Agreement shall be subject to the
satisfaction or waiver of the following conditions: (i) all representations and warranties of the Investor contained in this Subscription
Agreement are true and correct in all material respects (other than representations and warranties that are qualified as to materiality,
which representations and warranties shall be true in all respects) at and as of the Closing Date (except for those representations and
warranties that speak as of a specified earlier date, which shall be true and correct in all material respects as of such specified earlier
date (other than representations and warranties that are qualified as to materiality as of such specified earlier date, which
representations and warranties shall be true in all respects)), and consummation of the Closing shall constitute a reaffirmation by the
Investor that each of the representations and warranties of the Investor contained in this Subscription Agreement as of the Closing Date
are true and correct in all material respects (or, in the case of representations and warranties that are qualified as to materiality,
in all respects as of the Closing Date) and (ii) all obligations, covenants and agreements of the Investor required to be performed by
it at or prior to the Closing Date shall have been performed in all material respects.

 

(c)            The
obligation of the Investor to consummate the purchase of the Shares pursuant to this Subscription Agreement shall be subject to the
satisfaction or waiver of the following conditions: (i) all representations and warranties of SPAC and the Company contained in this
Subscription Agreement shall be true and correct in all material respects (other than representations and warranties that are
qualified as to materiality or Material Adverse Effect (as defined herein), which representations and warranties shall be true in
all respects) at and as of the Closing Date, and consummation of the Closing shall constitute a reaffirmation by SPAC and the
Company that each of the representations and warranties of SPAC and the Company contained in this Subscription Agreement as of the
Closing Date are true and correct in all material respects (or, in the case of representations and warranties that are qualified as
to materiality or Material Adverse Effect, in all respects) as of the Closing Date (except for those representations and warranties
that speak as of a specified earlier date, which shall be true and correct in all material respects as of such specified earlier
date (other than representations and warranties that are qualified as to materiality as of such specified earlier date,
which representations and warranties shall be true in all respects)); (ii) all obligations, covenants and agreements of SPAC and the
Company required by the Subscription Agreement to be performed by them at or prior to the Closing Date shall have been performed in
all material respects; and (iii) the BCA shall not have been amended or waived in a manner that materially and adversely affects the
economic benefits that the Investor (in its capacity as such) would reasonably expect to receive under this Subscription Agreement;
provided, that, the SEC’s (as defined herein) issuance of the Statement on Accounting and Reporting Considerations for
Warrants Issued by Special Purpose Acquisition Companies (the “Statement”), made on April 12, 2021, and any
consequences thereof or actions taken by SPAC directly in response thereto, shall not cause either of the conditions in this clause
(c) to be deemed to not have been satisfied so long as any such consequences or actions shall not have caused a material adverse
effect on the business, financial condition or results of operations of SPAC (a “Material Adverse Effect”). For
the avoidance of doubt, any restatement of the financial statements of SPAC and any amendments to previously filed SEC reports or
delays in filing SEC reports, in connection with the Statement or any subsequent related agreements or other guidance from the SEC
with respect to the Statement, shall not be considered to result in a Material Adverse Effect.

 

    2

     

    

 

4.             Further Assurances. At or prior to the Closing Date, the parties hereto shall execute and deliver or cause to be
executed and delivered such additional documents and take such additional actions as the parties reasonably may deem to be practical
and necessary in order to consummate the subscription as contemplated by this Subscription Agreement.

 

5.             SPAC
Representations and Warranties. SPAC represents and warrants to the Investor that:

 

(a)            SPAC is duly incorporated, validly existing and in good standing under the laws of the State of Delaware. SPAC has all power
(corporate or otherwise) and authority to own, lease and operate its properties and conduct its business as presently conducted and to
enter into, deliver and perform its obligations under this Subscription Agreement.

 

(b)           As of the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor against full payment
therefor in accordance with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable
and will not have been issued in violation of or subject to any preemptive or similar rights created under SPAC’s certificate of
incorporation and bylaws (each as amended on the Closing Date) by contract or under the General Corporation Law of the State of Delaware.

 

(c)            This Subscription Agreement has been duly authorized, executed and delivered by SPAC and, assuming that this Subscription
Agreement constitutes the valid and binding agreement of the Investor, this Subscription Agreement constitutes the valid and binding agreement
of SPAC and is enforceable against SPAC in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally,
or (ii) principles of equity, whether considered at law or equity.

 

(d)           The
execution and delivery of, and the performance of the transactions contemplated hereby, including the issuance and sale of the
Shares and the compliance by SPAC with all of the provisions of this Subscription Agreement and the consummation of the transactions
contemplated herein will be done in accordance with the Nasdaq marketplace rules (“Nasdaq”) and will not conflict
with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the
creation or imposition of any lien, charge or encumbrance upon any of the property or assets of SPAC or any of its subsidiaries
pursuant to the terms of (i) any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument
to which SPAC or any of its subsidiaries is a party or by which SPAC or any of its subsidiaries is bound or to which any of the
property or assets of SPAC is subject that would reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect or materially affect the validity of the Shares or the legal authority of SPAC to comply in all material respects
with the terms of this Subscription Agreement; (ii) result in any violation of the provisions of the organizational documents of
SPAC; or (iii) result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency
or body, domestic or foreign, having jurisdiction over SPAC or any of its properties that would reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect or materially affect the validity of the Shares or the legal authority
of SPAC to comply in all material respects with this Subscription Agreement.

 

    3

     

    

 

(e)           As
of their respective dates, all reports (the “SEC Reports”) required to be filed by SPAC with the SEC complied in all
material respects with the applicable requirements of the Securities Act of 1933, as amended (the “Securities Act”),
and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the SEC
promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The financial statements of SPAC included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing
and fairly present in all material respects the financial position of SPAC as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited financial statements, to normal, year-end audit adjustments.
A copy of each SEC Report is available to the Investor via the SEC’s EDGAR system. There are no material outstanding or unresolved
comments in comment letters from the staff of the Division of Corporation Finance of the SEC with respect to any of the SEC Reports.
SPAC has timely filed each report, statement, schedule, prospectus, and registration statement that SPAC was required to file with the
SEC since its inception.

 

(f)            Other than the Other Subscription Agreements, including any subscription agreement entered into consistent with Section
7(b) of this Subscription Agreement, the BCA and any other agreement contemplated by the BCA, including any Ancillary Documents as defined
therein, or described in the SEC Reports, SPAC has not entered into any side letter or similar agreement with any investor in connection
with such investor’s direct or indirect investment in SPAC (other than any side letter or similar agreement to the extent relating
to the transfer to any investor of (i) securities of SPAC by existing securityholders of SPAC, which may be effectuated as a forfeiture
to SPAC and reissuance, or (ii) securities to be issued to the direct or indirect securityholders of the Company pursuant to the BCA).
Except for any Alternative Settlement Procedures, no Other Subscription Agreement includes a lesser Per Share Purchase Price or other
terms and conditions that are materially more advantageous to any such Other Investor than Investor hereunder, and such Other Subscription
Agreements have not been amended, modified or waived in any material respect, or in any respect that materially benefits the Other Investors
thereunder unless the Investor has been offered substantially similar benefits in writing, following the date of this Subscription Agreement.

 

(g)           As of the date of this Subscription Agreement, the authorized capital stock of SPAC consists of (i) 400,000,000 shares
of Class A common stock, (ii) 40,000,000 shares of Class B common stock and (iii) 1,000,000 shares of preferred stock,
each with a par value of $0.0001 per share. As of the date of this Subscription Agreement, (A) 41,071,823 shares of Class A common
stock of SPAC are issued and outstanding, (B) 10,267,956 shares of Class B common stock of SPAC are issued and outstanding, (C) 30,750,267
warrants to purchase shares of Class A common stock of SPAC are issued and outstanding, and (D) no shares of preferred stock
are issued and outstanding. All (1) issued and outstanding shares of Class A common stock and Class B common stock of SPAC
have been duly authorized and validly issued, are fully paid and are non-assessable and (2) outstanding warrants have been
duly authorized and validly issued. Except as set forth above and pursuant to the Other Subscription Agreements, the BCA and the other
agreements and arrangements referred to therein or in the SEC Reports, as of the date hereof, there are no outstanding options, warrants
or other rights to subscribe for, purchase or acquire from SPAC any Class A common shares, Class B common shares or other equity
interests in SPAC, or securities convertible into or exchangeable or exercisable for such equity interests. As of the date hereof, SPAC
has no subsidiaries and does not own, directly or indirectly, interests or investments (whether equity or debt) in any person, whether
incorporated or unincorporated. There are no shareholder agreements, voting trusts or other agreements or understandings to which SPAC
is a party or by which it is bound relating to the voting of any securities of SPAC, other than (1) as set forth in the SEC Reports
and (2) as contemplated by the BCA.

 

(h)           Assuming
the accuracy of the Investor’s representations and warranties set forth in Section 7, no registration under the
Securities Act is required for the offer and sale of the Shares by SPAC to the Investor hereunder. The Shares (i) were not offered
by any form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) and
(ii) are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act,
or any state securities laws, or in a manner that would otherwise adversely affect reliance by SPAC on Section 4(a)(2) of the
Securities Act for the exemption from registration for the transactions contemplated hereby or would require registration of the
Shares under the Securities Act.

 

    4

     

    

 

(i)            Except for such matters as have not had and would not be reasonably likely to have, individually or in the aggregate, a
Material Adverse Effect, there is no (i) action, suit, claim or other proceeding, in each case by or before any governmental authority
pending, or, to the knowledge of SPAC, threatened against SPAC or (ii) judgment, decree, injunction, ruling or order of any governmental
entity or arbitrator outstanding against SPAC.

 

(j)            SPAC
is in compliance with all applicable laws, except where such noncompliance would not reasonably be expected to have a Material Adverse
Effect. As of the date hereof, SPAC has not received any written communication from a governmental authority that alleges that SPAC is
not in compliance with or is in default or violation of any applicable law, except where such non-compliance, default or violation would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. As of the date hereof, the issued and
outstanding Shares of SPAC are registered pursuant to Section 12(b) of the Exchange Act, and are listed for trading on Nasdaq, under
the symbol “MAAC” (it being understood that the trading symbol will be different for the Company upon completion of the Transaction).
There is no suit, action, proceeding or investigation pending or, to the knowledge of SPAC, threatened against SPAC by Nasdaq or the
SEC, respectively, to prohibit or terminate the listing of SPAC’s Shares on Nasdaq or to deregister the Shares under the Exchange
Act. Except as described in or contemplated by the BCA, SPAC has taken no action as of the date hereof that is designed to terminate
the registration of the Shares under the Exchange Act.

 

(k)            Other than the Placement Agents (as defined below), SPAC has not engaged any broker, finder, commission agent, placement
agent or arranger in connection with the sale of the Shares, and SPAC is not under any obligation to pay any broker’s fee or commission
in connection with the sale of the Shares other than to the Placement Agents.

 

(l)            SPAC is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other person
in connection with the execution, delivery and performance by SPAC of this Subscription Agreement (including, without limitation, the
issuance of the Shares), other than (i) filings with the SEC, (ii) filings required by applicable state securities laws, (iii) filings
required in accordance with Section 13 of this Subscription Agreement, (iv) filings required by Nasdaq, or such other applicable stock
exchange on which SPAC’s common stock is then listed, and (v) the failure of which to obtain would not be reasonably likely to have,
individually or in the aggregate, a Material Adverse Effect.

 

(m)          SPAC is not, and immediately after receipt of payment for the Shares will not be, an “investment company” within
the meaning of the Investment Company Act of 1940, as amended.

 

(n)           SPAC
acknowledges and agrees that, notwithstanding anything herein to the contrary, the Shares may be pledged by the Investor in connection
with a bona fide margin agreement, provided such pledge shall be (i) pursuant to an available exemption from the registration requirements
of the Securities Act or (ii) pursuant to, and in accordance with, a registration statement that is effective under the Securities Act
at the time of such pledge, and the Investor effecting a pledge of Shares shall not be required to provide SPAC with any notice thereof;
provided, however, that neither SPAC, the Company or their respective counsels shall be required to take any action (or refrain from
taking any action) in connection with any such pledge, other than providing any such lender of such margin agreement, upon the prior
written request of the Investor, with an acknowledgment that the Shares are not subject to a contractual prohibition on pledging or lock
up pursuant to this Subscription Agreement, the form of such acknowledgment to be subject to review and comment by SPAC in all respects.

 

6.             Company Representations and Warranties. The Company represents and warrants to the Investor that:

 

(a)                 The
Company is an exempted limited company duly organized, validly existing and in good standing (or the equivalent thereto with respect
to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the laws of the Bermuda. The
Company has all power (corporate or otherwise) and authority to own, lease and operate its properties and conduct its business as
presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement.

 

    5

     

    

 

(b)           This
Subscription Agreement has been duly authorized, executed and delivered by the Company and, assuming that this Subscription Agreement
constitutes the valid and binding agreement of the Investor, this Subscription Agreement is enforceable against the Company in accordance
with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium or other laws relating to or affecting the rights of creditors generally, or (ii) principles of equity, whether considered
at law or equity.

 

(c)           The
execution and delivery of, and the performance of the transactions contemplated hereby, and the compliance by the Company with all of
the provisions of this Subscription Agreement and the consummation of the transactions contemplated herein will not conflict with or
result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition
of any lien, charge or encumbrance upon any of the property or assets of the Company or any of its subsidiaries pursuant to the terms
of (i) any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which the Company or
any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets
of the Company or any of its subsidiaries is subject that would reasonably be expected to have a material adverse effect on the business,
financial condition or results of operations of the Company and its subsidiaries, taken as a whole (a “Company Material Adverse
Effect”) or materially affect the legal authority of the Company to comply in all material respects with the terms of this Subscription
Agreement; (ii) result in any violation of the provisions of the organizational documents of the Company; or (iii) result in any violation
of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction
over the Company or any of its properties that would reasonably be expected to have a Company Material Adverse Effect or materially affect
the legal authority of the Company to comply in all material respects with this Subscription Agreement.

 

(d)           Except for such matters as have not had and would not be reasonably expected to have, individually or in the aggregate,
a Company Material Adverse Effect, as of the date hereof, there is no (i) action, suit, claim or other proceeding, in each case by or
before any governmental authority pending, or, to the knowledge of the Company, threatened against the Company or (ii) judgment, decree,
injunction, ruling or order of any governmental entity or arbitrator outstanding against the Company.

 

(e)           As of the Closing Date, the issued and outstanding Company Shares will be registered pursuant to Section 12(b) of the Exchange
Act, and will be listed for trading on Nasdaq or another national stock exchange. There is no suit, action, proceeding or investigation
pending or, to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit the listing
of the Company Shares on Nasdaq or to deregister the Company Shares under the Exchange Act.

 

(f)            The
Company is in compliance with all applicable laws, except where such non-compliance would not reasonably be expected to have a Company
Material Adverse Effect. The Company has not received any written communication from a governmental authority that alleges that the Company
is not in compliance with or is in default or violation of any applicable law, except where such non-compliance, default or violation
would not reasonably be expected to have a Company Material Adverse Effect.

 

7.             Investor Representations and Warranties. The Investor represents and warrants to SPAC that:

 

(a)           The
Investor, or each of the funds managed by or affiliated with the Investor for which the Investor is acting as nominee, as
applicable, (i) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act), or an
institutional “accredited investor” (within the meaning of Rule 501(a) under the Securities Act), in each case,
satisfying the applicable requirements set forth on Schedule A, (ii) is an “institutional account” (as defined in
FINRA Rule 4512(c)), (iii) is acquiring the Shares only for his, her or its own account and not for the account of others, or if the
Investor is subscribing for the Shares as a fiduciary or agent for one or more investor accounts, the Investor has full investment
discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations and
agreements herein on behalf of each owner of each such account, and (iv) is not acquiring the Shares with a view to, or for offer or
sale in connection with, any distribution thereof in violation of the Securities Act (and shall provide the requested information
set forth on Schedule A). The Investor is not an entity formed for the specific purpose of acquiring the Shares.

 

    6

     

    

 

(b)           Notwithstanding anything to the contrary set forth herein, the Investor acknowledges and agrees that, subsequent to
the date of this Subscription Agreement and prior to the Closing, SPAC may enter into one or more additional subscription agreements with
additional investors with terms and conditions that are not materially more advantageous to the investor thereunder than this Subscription
Agreement, and entry into such agreements may increase the aggregate amount of Shares being subscribed for in the private placement contemplated
by this Subscription Agreement. For the avoidance of doubt, such additional agreements shall reflect not less than the same Per Share
Purchase Price and shall constitute Other Subscription Agreements for purposes of this Agreement, mutatis mutandis.

 

(c)            The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering
within the meaning of the Securities Act and that the Shares have not been registered under the Securities Act. The Investor acknowledges
and agrees that, other than with respect to any actions taken to consummate the Transaction pursuant to the BCA, the Shares may not be
offered, resold, transferred, pledged or otherwise disposed of by the Investor absent an effective registration statement under the Securities
Act except (i) to SPAC or an affiliate thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur outside the United States
within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable exemption from the registration requirements
of the Securities Act, and in each of clauses (i) and (iii) in accordance with any applicable securities laws of the states and other
jurisdictions of the United States, and that any certificates representing the Shares shall contain a restrictive legend to such effect.
The Investor acknowledges and agrees that the Shares will be subject to the foregoing transfer restrictions and, as a result of these
transfer restrictions, other than with respect to any actions taken to consummate the Transaction pursuant to the BCA, the Investor may
not be able to readily offer, resell, transfer, pledge or otherwise dispose of the Shares and may be required to bear the financial risk
of an investment in the Shares for an indefinite period of time. The Investor acknowledges and agrees that, other than with respect to
any actions taken to consummate the Transaction pursuant to the BCA, the Shares will not immediately be eligible for offer, resale, transfer,
pledge or disposition pursuant to Rule 144 promulgated under the Securities Act. The Investor acknowledges and agrees that it has been
advised to consult legal counsel and tax and accounting advisors prior to making any offer, resale, transfer, pledge or disposition of
any of the Shares.

 

(d)           The Investor acknowledges and agrees that the Investor is purchasing the Shares directly from SPAC. The Investor further
acknowledges that there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of SPAC,
the Company, the Placement Agents or any of their respective affiliates or any control persons, officers, directors, employees, partners,
agents or representatives of any of the foregoing or any other person or entity, expressly or by implication, other than those representations,
warranties, covenants and agreements of SPAC and the Company expressly set forth in Section 5 and Section 6 of this Subscription Agreement,
respectively.

 

(e)           The Investor’s acquisition and holding of the Shares will not constitute or result in a non-exempt prohibited transaction
under section 406 of the Employee Retirement Income Security Act of 1974, as amended, section 4975 of the Internal Revenue Code of 1986,
as amended, or any applicable similar law.

 

(f)            The Investor acknowledges and agrees that the Investor has received such information as the Investor deems necessary in
order to make an investment decision with respect to the Shares, including, with respect to SPAC, the Transaction and the business of
the Company and its subsidiaries. Without limiting the generality of the foregoing, the Investor acknowledges that he, she or it has reviewed
SPAC’s filings with the SEC. The Investor acknowledges and agrees that the Investor and the Investor’s professional advisor(s),
if any, have had the full opportunity to ask such questions, receive such answers and obtain such information as the Investor and such
Investor’s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares.

 

(g)           The
Investor became aware of this offering of the Shares solely by means of direct contact between the Investor and SPAC, the Company or
a representative of SPAC or the Company, or by means of contact from any of the Placement Agents in their capacity as such, and the
Shares were offered to the Investor solely by direct contact between the Investor and SPAC, the Company or a representative of SPAC
or the Company, or by contact between the Investor and one or more Placement Agents in their capacity as such. The Investor did not
become aware of this offering of the Shares, nor were the Shares offered to the Investor, by any other means. The Investor
acknowledges that the Shares (i) were not offered to it by any form of general solicitation or general advertising, including
methods described in section 502(c) of Regulation D under the Securities Act and (ii) to its knowledge, are not being offered in a
manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws.
The Investor acknowledges that it is not relying upon, and has not relied upon, any statement, representation or warranty made by
any person, firm or corporation (including, without limitation, SPAC, the Company, the Placement Agents, any of their respective
affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing),
other than the representations and warranties of SPAC and the Company contained in Section 5 and Section 6 of this Subscription
Agreement, respectively, in making its investment or decision to invest in SPAC.

 

    7

     

    

 

(h)           The Investor acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the
Shares, including those set forth in SPAC’s filings with the SEC. The Investor has such knowledge and experience in financial and
business matters as to be capable of evaluating the merits and risks of an investment in the Shares, and the Investor has sought such
accounting, legal and tax advice as the Investor has considered necessary to make an informed investment decision and the Investor has
made its own assessment and has satisfied itself concerning relevant tax and other economic considerations relative to its purchase of
the Shares.. The Investor is able to sustain a complete loss on its investment in the Shares, has no immediate need for liquidity with
respect to its investment in the Shares.

 

(i)            Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks
of an investment in the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able
at this time and in the foreseeable future to bear the economic risk of a total loss of the Investor’s investment in SPAC. The Investor
acknowledges specifically that a possibility of total loss exists.

 

(j)            In making its decision to purchase the Shares, the Investor has relied solely upon independent investigation made by the
Investor and SPAC’s and the Company’s representations and warranties expressly set forth in Section 5 and Section 6 of this
Subscription Agreement, respectively, and no other representations and warranties of any kind, whether express or implied, of SPAC or
any other person. Without limiting the generality of the foregoing, the Investor has not relied on any statements or other information
provided by or on behalf of the Placement Agents or any of their respective affiliates or any control persons, officers, directors, employees,
partners, agents or representatives of any of the foregoing concerning SPAC, the Company, the Transaction, the BCA, this Subscription
Agreement or the transactions contemplated hereby or thereby, the Shares or the offer and sale of the Shares.

 

(k)           The
Investor acknowledges that the Placement Agents: (i) are each acting solely as the SPAC’s Placement Agent in connection with
the transactions contemplated by the Subscription Agreements and is not acting as an underwriter or in any other capacity and is not
and shall not be construed as a fiduciary for the Investor, (ii) have not made or make any representation or warranty, express or
implied, of any kind or character and have not provided any advice or recommendation in connection with the transactions
contemplated by the Subscription Agreements, (iii) will have no responsibility with respect to (a) any representations, warranties
or agreements made by any person or entity under or in connection with the Transaction or any of the documents furnished pursuant
thereto or in connection therewith, or the execution, legality, validity or enforceability (with respect to any person) of any
thereof, or (b) the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning
the SPAC, the Company or the Transaction, (iv) have not acted as the Investor’s financial advisor or fiduciary in connection
with the issue and purchase of Shares, (v) may have acquired, or during the term of the Shares may acquire, non-public information
with respect to the Company, which, subject to the requirements of applicable law, the Investor agrees need not be provided to it,
(vi) may have existing or future business relationships with SPAC and the Company (including, but not limited to, lending,
depository, risk management, advisory and banking relationships) and will pursue actions and take steps that it deems or they deem
necessary or appropriate to protect its or their interests arising therefrom without regard to the consequences for a holder of
Shares, and that certain of these actions may have material and adverse consequences for a holder of Shares; and (vii) shall have no
liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties,
judgments, awards, liabilities, costs, expenses or disbursements incurred by the Investor, the Company or any other person or
entity), whether in contract, tort or otherwise, to the Investor, or to any person claiming through the Investor, in respect of the
Transaction.

 

    8

     

    

 

(l)             The Investor acknowledges that it has not relied on the Placement Agents in connection with its determination as to the
legality of its acquisition of the Shares or as to the other matters referred to herein and the Investor has not relied on any investigation
that the Placement Agents, any of their affiliates or any person acting on their behalf have conducted with respect to the Shares, SPAC
or the Company. The Investor further acknowledges that it has not relied on any information contained in any research reports prepared
by the Placement Agents or any of their affiliates.

 

(m)          The Investor acknowledges that J.P. Morgan Securities LLC and SVB Leerink LLC
are each acting as financial advisors to the Company (i) in connection with the Transaction and (ii) in connection with the Company’s
contemplated acquisition of all issued and outstanding shares of common stock of Immunovant, Inc. not currently owned by the Company (the
 “Immunovant Acquisition”), as disclosed on Schedule 13D filed on March 8, 2021 by the Company (it being understood
and agreed by the Investor that the purchase of the Shares pursuant to this Subscription Agreement on the Closing Date and the closing
of the Transaction shall not be contingent on the consummation of the contemplated Immunovant Acquisition).

 

(n)           The Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the offering
of the Shares or made any findings or determination as to the fairness of this investment.

 

(o)           The Investor, if not an individual, has been duly formed or incorporated and is validly existing and is in good standing
under the laws of its jurisdiction of formation or incorporation, with power and authority to enter into, deliver and perform its obligations
under this Subscription Agreement.

 

(p)            The
execution, delivery and performance by the Investor of this Subscription Agreement are within the powers of the Investor, have been duly
authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation of any court
or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to which the Investor is a party
or by which the Investor is bound, and, if the Investor is not an individual, will not violate any provisions of the Investor’s
organizational documents, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership
or operating agreement, as may be applicable. The signature of the Investor on this Subscription Agreement is genuine, and the signatory,
if the Investor is an individual, has legal competence and capacity to execute the same or, if the Investor is not an individual, the
signatory has been duly authorized to execute the same, and, assuming that this Subscription Agreement constitutes the valid and binding
obligation of SPAC, this Subscription Agreement constitutes a legal, valid and binding obligation of the Investor, enforceable against
the Investor in accordance with its terms except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii) principles of equity, whether
considered at law or equity.

 

(q)           The
Investor is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by the
U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”)
or in any Executive Order issued by the President of the United States and administered by OFAC (“OFAC
List”), or a person or entity prohibited by any OFAC sanctions program; (ii) owned, directly or indirectly, or
controlled by, or acting on behalf of, one or more persons that are named on the OFAC List; (iii) organized, incorporated,
established, located, resident or born in, or a citizen, national or the government, including any political subdivision, agency or
instrumentality thereof, of, Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine or any other country or territory
embargoed or subject to substantial trade restrictions by the United States; (iv) a Designated National as defined in the Cuban
Assets Control Regulations, 31 C.F.R. Part 515; or (v) a non-U.S. shell bank or providing banking services indirectly to a non-U.S.
shell bank (each, a “Prohibited Investor”). The Investor agrees to
provide law enforcement agencies, if requested thereby, such records as required by applicable law, provided that the Investor is
permitted to do so under applicable law. If the Investor is a financial institution subject to the Bank Secrecy Act (31 U.S.C.
Section 5311 et seq.) (the “BSA”), as amended by the USA PATRIOT Act of
2001 (the “PATRIOT Act”), and its implementing regulations
(collectively, the “BSA/PATRIOT Act”), the Investor maintains policies
and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. To the extent required, it
maintains policies and procedures reasonably designed to ensure compliance with OFAC-administered sanctions programs, including for
the screening of its investors against the OFAC sanctions programs, including the OFAC List. To the extent required by applicable
law, the Investor maintains policies and procedures reasonably designed to ensure that the funds held by the Investor and used to
purchase the Shares were legally derived and were not obtained, directly or indirectly, from a Prohibited Investor.

 

    9

     

    

 

(r)             The Investor acknowledges that no disclosure or offering document has been prepared by J.P.
Morgan Securities LLC, SVB Leerink LLC, Citigroup Global Markets Inc., any additional placement agent that may be engaged by SPAC, or
any of their respective affiliates (collectively, the “Placement Agents”)
in connection with the offer and sale of the Shares.

 

(s)            The Investor acknowledges that neither Placement Agents, nor any of their respective affiliates nor any control persons,
officers, directors, employees, partners, agents or representatives of any of the foregoing have made any independent investigation with
respect to SPAC, the Company or its subsidiaries or any of their respective businesses, or the Shares or the accuracy, completeness or
adequacy of any information supplied to the Investor by SPAC.

 

(t)            The Investor, when required to deliver payment to SPAC pursuant
to Section 2 above, will have, sufficient funds to pay the Subscription Amount and consummate the purchase and sale of the Shares pursuant
to this Subscription Agreement.

 

(u)            The
Investor agrees that, from the date of this Subscription Agreement until the Closing or the earlier termination of this Subscription
Agreement, none of Investor, its controlled affiliates, or any person or entity acting on behalf of the Investor or any of its controlled
affiliates or pursuant to any understanding with the Investor or any of its controlled affiliates will engage in any Short Sales with
respect to securities of the SPAC. For the purposes hereof, “Short Sales” shall include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock
pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options,
puts, calls, swaps and similar arrangements (including on a total return basis), including through non-U.S. broker dealers or foreign
regulated brokers. Notwithstanding the foregoing, (A) nothing herein shall prohibit (x) other entities under common management with the
Investor with whom the Investor is not acting in concert with respect to any trading in securities of the SPAC, this Subscription Agreement
or the Investor’s participation in this offering of the Shares including the Investor’s controlled affiliates and/or affiliates,
or (y) in the case of an Investor that is externally managed, advised or sub-advised by another person, any other person that is not
directly controlled or managed by such manager, adviser or sub-adviser, in each case from entering into any Short Sale and (B) in the
case of an Investor that is a multi-managed investment bank or vehicle whereby separate portfolio managers manage separate portions of
such Investor’s assets and the portfolio managers have no knowledge of the investment decisions made by the portfolio managers
managing other portions of such Investor’s assets, this Section (u) shall apply only with respect to the portion of assets managed
by the portfolio manager that made the investment decision to purchase the Shares covered by this Subscription Agreement. For the avoidance
of doubt, nothing in this Section (u) shall restrict any transactions with respect to securities of SPAC other than transactions that
are Short Sales including the exercise of any redemption with respect to securities of the SPAC.

 

(v)           Except as expressly disclosed in a Schedule 13D or Schedule 13G (or amendments thereto) filed by such Investor with the
SEC with respect to the beneficial ownership of the SPAC’s common stock, the Investor is not currently (and at all times through
Closing will refrain from being or becoming) a member of a “group” (within the meaning of section 13(d)(3) or section 14(d)(2)
of the Exchange Act) acting for the purpose of acquiring, holding or disposing of equity securities of the SPAC (within the meaning of
Rule 13d-5(b)(1) under the Exchange Act).

 

(w)          No
broker, finder or other financial consultant has acted on behalf of the Investor in connection with this Subscription Agreement or the
transactions contemplated hereby.

 

(x)            The
Investor acknowledges the SEC’s issuance of the Statement, and the Investor agrees that any actions taken by SPAC in
connection with, or as may be necessary or advisable to address the potential implications of, such Statement or review shall not be
deemed to constitute a breach of any of the representations, warranties or covenants in this Subscription Agreement; provided,
however, that any such actions may not materially and adversely affect the rights of the Investor (in its capacity as such) under
this Subscription Agreement. For the avoidance of doubt, any restatement or the financial statements of SPAC and any amendments to
previously filed SEC reports or delays in filing SEC reports, in connection with the Statement or any subsequent related agreements
or other guidance from the SEC with respect to the Statement shall not be considered to materially and adversely affect the rights
of the Investor (in its capacity as such) under this Subscription agreement.

 

    10

     

    

 

8.             Registration Rights.

 

(a)                 In
the event that the Shares are not registered in connection with the consummation of the Transaction, the Company agrees that, within
thirty (30) calendar days after the Closing Date (the “Filing Deadline”), it will file with the SEC (at its sole
cost and expense) a registration statement (the “Registration Statement”) registering the resale of the Shares, and it
shall use its commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the
filing thereof, but no later than the earlier of (i) sixty (60) calendar days after the filing thereof (or ninety (90) calendar days
after the filing thereof if the SEC notifies the Company that it will “review” the Registration Statement) and (ii) five
(5) business days after the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Registration
Statement will not be “reviewed” or will not be subject to further review ((i) and (ii) collectively, the
 “Effectiveness Deadline”). In connection with the foregoing and with all transactions contemplated by this
Subscription Agreement, Investor shall not be required to execute any lock-up or similar agreement or otherwise be subject to any
contractual restriction on the ability to transfer the Shares. The Company agrees to use commercially reasonable efforts to cause
such Registration Statement, or another shelf registration statement that includes the Shares to be sold pursuant to this
Subscription Agreement, to remain effective until the earliest of (i) the second anniversary of the Closing, (ii) the date on which
the Investor ceases to hold any Shares issued pursuant to this Subscription Agreement, or (iii) on the first date on which the
Investor is able to sell all of its Shares issued pursuant to this Subscription Agreement (or shares received in exchange therefor)
under Rule 144 promulgated under the Securities Act (“Rule 144”) within ninety (90) calendar days without the
public information, volume or manner of sale limitations of such rule (such date, the “End Date”). Prior to the
End Date, the Company will use commercially reasonable efforts to (1) qualify the Shares for listing on Nasdaq or another
applicable national stock exchange and (2) update or amend the Registration Statement as necessary to include the Shares.
Subject to receipt from the Investor by the Company and its transfer agent of customary representations and other documentation
reasonably acceptable to the Company and the transfer agent in connection therewith, including, if required by the transfer agent,
an opinion of the Company’s counsel in a form reasonably acceptable to the transfer agent, the Investor may request that the
Company remove any legend from the book-entry position evidencing the Shares following the earliest of such time as the Shares (A)
have been or are being sold or transferred pursuant to an effective registration statement or (B) have been or are being sold
pursuant to Rule 144 promulgated under the Securities Act (“Rule 144”). To the extent required by the
Company’s transfer agent, the Company shall use commercially reasonable efforts to cause its legal counsel to deliver a
customary opinion within two business days of the delivery of all reasonably necessary representations and other documentation from
the Investor as reasonably requested by the Company’s transfer agent. If restrictive legends are no longer required for the
Shares pursuant to the foregoing, the Company shall, reasonably promptly following any request therefor from the Investor as
described above (and no later than five (5) business days after such request), deliver to the transfer agent instructions to remove
such restrictive legends from the Shares of the Investor. The Company may amend the Registration Statement so as to convert the
Registration Statement to a Registration Statement on Form S-3 at such time after the Company becomes eligible to use such Form S-3.
For as long as the Investor holds the Shares, the Company will use commercially reasonable efforts to file all reports, and provide
all customary and reasonable cooperation, necessary to enable the Investor to resell the Shares pursuant to the Registration
Statement or Rule 144 of the Securities Act (when Rule 144 of the Securities Act becomes available to the Investor), as applicable.
In no event shall the undersigned be identified as a statutory underwriter in the Registration Statement unless in response to a
comment or request from the staff of the SEC or another regulatory agency; provided, however, that if the SEC requests that the
undersigned be identified as a statutory underwriter in the Registration Statement, the undersigned will have an opportunity to
withdraw from the Registration Statement. For purposes of clarification, any failure by the Company to file the Registration
Statement by the Filing Deadline or to effect such Registration Statement by the Effectiveness Deadline shall not otherwise relieve
the Company of its obligations to file the Registration Statement or effect the registration of the Shares set forth in this Section
8. The Investor acknowledges and agrees that the Company may suspend the use of any such registration statement if it determines in
good faith, upon advice of legal counsel (internal counsel being sufficient), that in order for such registration statement not to
contain a material misstatement or omission, an amendment thereto would be needed to include information that would at that time not
otherwise be required in a current, quarterly, or annual report under the Exchange Act, provided, that, (I) the Company shall not so
delay filing or so suspend the use of the Registration Statement on more than three (3) occasions for a period of more than sixty
(60) consecutive days or more than a total of ninety (90) calendar days, in each case in any three hundred sixty (360) day period
and (II) the Company shall use commercially reasonable efforts to make such Registration Statement available for the sale by the
Investor of such securities as soon as practicable thereafter. The Company’s obligations to include the Shares issued pursuant
to this Subscription Agreement (or shares issued in exchange therefor) for resale in the Registration Statement are contingent upon
the Investor furnishing in writing to the Company such information regarding the Investor, the securities of the Company held by the
Investor and the intended method of disposition of such Shares, as shall be reasonably requested by the Company to effect the
registration of such Shares, and shall execute such documents in connection with such registration as the Company may reasonably
request that are customary of a selling stockholder in similar situations. The Company shall use its commercially reasonable efforts
to provide a draft of the Registration Statement to the Investor for review at least two (2) business days in advance of filing the
Registration Statement; provided that, for the avoidance of doubt, in no event shall the Company be required to delay or postpone
the filing of such Registration Statement as a result of or in connection with the Investor’s review.

 

    11

     

    

 

(b)           Notwithstanding
the foregoing, if the SEC prevents the Company from including any or all of the Shares proposed to be registered under the Registration
Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of Shares by the applicable stockholders or
otherwise, such Registration Statement shall register for resale such number of Shares which is equal to the maximum number of Shares
as is permitted by the SEC. In such event, the number of Shares to be registered for each selling stockholder named in the Registration
Statement shall be reduced pro rata among all such selling stockholders and as promptly as practicable after being permitted to register
additional Shares under Rule 415 under the Securities Act, the Company shall amend the Registration Statement or file a new Registration
Statement to register such Shares not included in the initial Registration Statement and use its commercially reasonable efforts to cause
such amendment or Registration Statement to become effective as promptly as practicable.

 

(c)           In the case of the registration, qualification, exemption or compliance effected by the Company pursuant to this Agreement,
the Company shall, upon reasonable request, inform Investor as to the status of such registration, qualification, exemption and compliance.
At its expense, the Company shall use its commercially reasonable efforts to advise Investor reasonably promptly (but within no later
than 5 business days):

 

(i)                 
when a Registration Statement or any amendment thereto has been filed with the SEC and when a Registration Statement or
any post-effective amendment thereto has become effective;

 

(ii)               
after it shall receive notice or obtain knowledge thereof, of the issuance by the SEC of any stop order suspending the effectiveness
of any Registration Statement or the initiation of any proceedings for such purpose;

 

(iii)             
of the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares included
therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 

(iv)              
subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any
changes in any Registration Statement or prospectus included therein so that, as of such date, the statements therein are not misleading
and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus,
in the light of the circumstances under which they were made) not misleading.

 

Upon receipt of any written notice from the
Company (which notice shall not contain any material non-public information regarding the Company) of the happening any event
contemplated in clauses (ii) through (iv) above during the period that the Registration Statement is effective or if as a result of
the occurrence of such event the Registration Statement or related prospectus contains any untrue statement of a material fact or
omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made (in the case of the prospectus) not misleading, the undersigned Investor agrees that (1) it
will immediately discontinue offers and sales of the Shares under the Registration Statement (excluding, for the avoidance of doubt,
sales conducted pursuant to Rule 144) until the undersigned Investor receives copies of a supplemental or amended prospectus (which
Company agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and receives notice that any
post-effective amendment has become effective or unless otherwise notified by Company that it may resume such offers and sales, and
(2) it will maintain the confidentiality of any information included in such written notice delivered by Company except (A) for
disclosure to the Investor’s employees, agents and professional advisers who need to know such information and are obligated
to keep it confidential, (B) for disclosures to the extent required in order to comply with reporting obligations to its limited
partners who have agreed to keep such information confidential and (C) as required by law or subpoena. The Company shall use its
commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable. Upon the occurrence of any event contemplated in clauses (ii) through (iv) above, except for such
times as the Company is permitted hereunder to suspend, and has suspended, the use of a prospectus forming part of a Registration
Statement, the Company shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective
amendment to such Registration Statement or a supplement to the related prospectus, or file any other required document so that, as
thereafter delivered to purchasers of the Shares included therein, such prospectus will not include any untrue statement of a
material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading.

 

    12

     

    

 

(d)           Indemnification.

 

(i)                 
The Company shall indemnify Investor (to the extent a seller under the Registration Statement), its officers, directors,
advisers and agents, and each person who controls Investor (within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act) to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs
(including reasonably incurred and documented attorneys’ fees) and reasonably incurred and documented expenses (collectively, “Losses”)
that arise out of or are based upon any untrue or alleged untrue statement of a material fact contained or incorporated by reference in
the Registration Statement pursuant to which Investor’s Shares are registered, any prospectus included in the Registration Statement
or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to
any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in
the case of any prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not
misleading, except to the extent that such untrue statements or alleged untrue statements, omissions or alleged omissions are based upon
information regarding Investor furnished in writing to the Company by Investor expressly for use therein or Investor has omitted a material
fact from such information.

 

(ii)               
The Investor shall indemnify and hold harmless the Company, its directors, officers, agents and employees, and each person
who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), to the fullest extent
permitted by applicable law, from and against all Losses arising out of or are based upon any untrue or alleged untrue statement of a
material fact contained or incorporated by reference in any Registration Statement pursuant to which Investor’s Shares are registered,
any prospectus included in the Registration Statement, or any form of prospectus, or in any amendment or supplement thereto or in any
preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein
or necessary to make the statements therein (in the case of any prospectus, or any form of prospectus or supplement thereto, in light
of the circumstances under which they were made) not misleading to the extent, but only to the extent, that such untrue statements or
omissions are based upon information regarding Investor furnished in writing to the Company by the Investor expressly for use therein.
In no event shall the liability of Investor be greater in amount than the dollar amount of the net proceeds received by Investor upon
the sale of the subscribed Shares giving rise to such indemnification obligation. The Investor shall notify the Company promptly of the
institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this Section 8
of which the Investor is aware.

 

    13

     

    

 

(iii)              Any
person entitled to indemnification herein shall (1) give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person’s right to
indemnification hereunder to the extent such failure has not prejudiced the indemnifying party) and (2) permit such indemnifying
party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed,
the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its written
consent. An indemnifying party who elects not to assume the defense of a claim shall not be obligated to pay the fees and expenses
of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable
judgment of legal counsel to any indemnified party a conflict of interest exists between such indemnified party and any other of
such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party
(which consent shall not be unreasonably withheld, conditioned or delayed), consent to the entry of any judgment or enter into any
settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party
pursuant to the terms of such settlement) or which settlement does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.

 

(iv)              
The indemnification provided for under this Subscription Agreement shall remain in full force and effect regardless of any
investigation made by or on behalf of the indemnified party or any officer, director, employee, agent, affiliate or controlling person
of such indemnified party and shall survive the transfer of the Shares purchased pursuant to this Subscription Agreement.

 

(v)               
If the indemnification provided under this Section 8(d) from the indemnifying party is unavailable or insufficient to hold
harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the indemnifying
party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result
of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying
party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party
and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or
alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by, or relates to information
supplied by, such indemnifying party or indemnified party, and the indemnifying party’s and indemnified party’s relative intent,
knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result
of the losses or other liabilities referred to above shall be deemed to include, subject to the limitations set forth in this Section
8(d), any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
pursuant to this Section (8(d)(v) from any person who was not guilty of such fraudulent misrepresentation. Each indemnifying party’s
obligation to make a contribution pursuant to this Section 8(d)(v) shall be individual, not joint and several, and in no event shall the
liability of any Investor hereunder be greater in amount than the dollar amount of the net proceeds received by such Investor upon the
sale of the subscribed Shares giving rise to such indemnification obligation.

 

(e)           The
Company shall not hereafter enter into, and is not currently a party to, any Other Subscription Agreements with respect to the Shares
that is inconsistent in any material respect with, or superior to, the registration rights granted to Investor by this Subscription Agreement.
Notwithstanding any other rights and remedies Investor may have in respect of the Company or such Other Investors pursuant to this Subscription
Agreement, if the Company enters into any other registration rights or similar agreement with respect to the Shares that contains provisions
that violate the preceding sentence, the terms and conditions of this Subscription Agreement shall be deemed to have been amended without
further action by the Company or Investor so that Investor shall be entitled to the benefit of any such more favorable or less restrictive
terms or conditions, as the case may be.

 

    14

     

    

 

9.              Termination.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the
parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earlier to
occur of (a) such date and time as the BCA is terminated in accordance with its terms without being consummated, (b) upon the mutual
written agreement of each of the parties hereto to terminate this Subscription Agreement, (c) December 30, 2021, if the Closing has
not occurred by such date, or (d) if any of the conditions to Closing set forth in Section 3 of this Subscription Agreement are (i)
not satisfied or waived or (ii) not capable of being satisfied and, in each case of (i) and (ii), as a result thereof, the
transactions contemplated by this Subscription Agreement will not be and are not consummated at the Closing (the termination events
described in clauses (a)–(d) above, collectively, the “Termination Events”); provided that in the case of
clause (d), to the extent such failure to satisfy the conditions to Closing set forth in Section 3 of this Subscription Agreement is
caused by the Investor’s failure to satisfy such conditions, termination shall instead be at the election of SPAC; provided,
further, that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination,
and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from any such
willful breach. SPAC shall notify the Investor in writing of the termination of the BCA promptly after the termination of such
agreement. Upon the occurrence of any Termination Event and subject to the provisions of this Section 9, this Subscription Agreement
shall be void and of no further effect and any monies paid by the Investor to SPAC in connection herewith shall promptly (and in any
event within one (1) business day) following the Termination Event be returned to the Investor.

 

10.            Trust
Account Waiver. The Investor acknowledges that SPAC is a blank check company with the powers and privileges to effect a merger, asset
acquisition, reorganization or similar business combination involving SPAC and one or more businesses or assets. The Investor further
acknowledges that, as described in SPAC’s prospectus relating to its initial public offering dated October 6, 2020 (the “Prospectus”)
available at www.sec.gov, substantially all of SPAC’s assets consist of the cash proceeds of SPAC’s initial public offering
and private placement of its securities, and substantially all of those proceeds have been deposited in a trust account (the “Trust
Account”) for the benefit of SPAC, its public shareholders and the underwriters of SPAC’s initial public offering.
Except with respect to interest earned on the funds held in the Trust Account that may be released to SPAC to pay its tax obligations
and to fund certain of its working capital requirements, the cash in the Trust Account may be disbursed only for the purposes set forth
in the Prospectus. For and in consideration of SPAC entering into this Subscription Agreement, the receipt and sufficiency of which are
hereby acknowledged, the Investor hereby irrevocably waives any and all right, title and interest, or any claim of any kind it has or
may have in the future, in or to any monies held in the Trust Account, and agrees not to seek recourse against the Trust Account as a
result of, or arising out of, this Subscription Agreement; provided, however, that nothing in this Section 10 shall be deemed to limit
the Investor’s right, title, interest or claim to any monies held in the Trust Account by virtue of its record or beneficial ownership
of Shares (x) acquired by any means other than pursuant to this Subscription Agreement or (y) currently outstanding on the date hereof,
pursuant to a validly exercised redemption right with respect to any such Shares, except to the extent that the Investor has otherwise
agreed in writing with SPAC to not exercise such redemption right.

 

11.           Miscellaneous.

 

(a)           Neither this Subscription Agreement nor any rights that may accrue to the parties hereunder (other than the Shares acquired
hereunder, if any) may be transferred or assigned without the prior written consent of each of the other parties hereto; provided that
(i) this Subscription Agreement and any of the Investor’s rights and obligations hereunder may be assigned to an affiliate or any
fund or account advised or managed by the Investor or the same investment manager or investment advisor as the Investor or by an affiliate
(as defined in Rule 12b-2 of the Exchange Act) of such investment manager or investment advisor without the prior consent of SPAC or the
Company; provided, however, the Investor shall provide notice of any such assignment to SPAC and the Company and (ii) the Investor's rights
under Section 8 may be assigned to an assignee or transferee of the Shares; provided further that prior to such assignment any such assignee
shall agree in writing to be bound by the terms hereof. Upon such assignment by the Investor in accordance with this Section (a), the
assignee shall become an Investor hereunder and have the rights and obligations provided for herein to the extent of such assignment;
provided, that no assignment pursuant to clause (i) of this Section 11(a) shall relieve the Investor of its obligations hereunder, except
to the extent actually performed in accordance with the terms hereof, unless consented to in writing by SPAC and the Company (such consent
not to be unreasonably conditioned, delayed or withheld).

 

(b)           SPAC
and/or the Company may request from the Investor such additional information as they may reasonably deem necessary to register the
resale of the Shares and evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall promptly provide
such information as may reasonably be requested to the extent readily available; provided, that, each of SPAC and the Company agrees
to keep any such information provided by Investor confidential except (i) as necessary to include in any registration statement
required to be filed hereunder, (ii) as required by the federal securities law or pursuant to other routine proceedings of
regulatory authorities or (iii) to the extent such disclosure is required by law, at the request of the staff of the SEC or
regulatory agency or under the regulations of any national securities exchange on which SPAC’s or the Company’s
securities, as the case may be, are listed for trading. The Investor acknowledges and agrees that if it does not provide SPAC and/or
the Company with such requested information, the Investor's Shares may not be registered for resale pursuant to Section 8 hereof.
The Investor acknowledges that SPAC and/or the Company may file a copy of this Subscription Agreement (or a form of this
Subscription Agreement) with the SEC as an exhibit to a periodic report or a registration statement of SPAC or the Company.

 

    15

     

    

 

(c)            The
Investor acknowledges that (i) SPAC and the Company will rely on the acknowledgments, understandings, agreements, representations and
warranties of the Investor contained in this Subscription Agreement, including Schedule A hereto and (ii) the Placement Agents will rely
on the acknowledgments, understandings, agreements, representations and warranties of the Investor contained in Section 7 of this Subscription
Agreement, including Schedule A hereto. Each of SPAC and the Company acknowledges that the Investor will rely on the acknowledgments,
understandings, agreements, representations and warranties of each of SPAC and the Company contained in this Subscription Agreement.
Prior to the Closing, the Investor agrees to promptly notify SPAC and the Company if any of the acknowledgments, understandings, agreements,
representations and warranties set forth in Section 7 above are no longer accurate in any material respect (other than those acknowledgments,
understandings, agreements, representations and warranties qualified by materiality, in which case the Investor shall notify SPAC if
they are no longer accurate in any respect). Investor further acknowledges and agrees that each of the Placement Agents is a third-party
beneficiary of the representations and warranties of the Investor contained in this Subscription Agreement. The Investor acknowledges
and agrees that the purchase by the Investor of Shares from SPAC will constitute a reaffirmation of the acknowledgments, understandings,
agreements, representations and warranties herein (as modified by any such notice) by the Investor as of the time of such purchase.

 

(d)           Each
of SPAC, the Company, the Investor and the Placement Agents is each entitled to rely upon this Subscription Agreement and each is irrevocably
authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding
or official inquiry with respect to the matters covered hereby; provided, however, that the foregoing clause of this Section 11(d) shall
not give the Company or the Placement Agents any rights other than those expressly set forth in this Section 11(d) and, without limiting
the generality of the foregoing and for the avoidance of doubt, in no event shall the Company be entitled to rely on any of the representations
and warranties of SPAC set forth in this Subscription Agreement.

 

(e)           All
of the agreements, representations and warranties made by each party hereto in this Subscription Agreement shall survive the Closing.

 

(f)            This
Subscription Agreement may not be amended, modified, waived or terminated (other than pursuant to the terms of Section 9 above) except
by an instrument in writing, signed by each of the parties hereto. No failure or delay of either party in exercising any right or remedy
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment
or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or
the exercise of any other right or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any
rights or remedies that they would otherwise have hereunder.

 

(g)           This Subscription Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other prior
agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter
hereof. Except as expressly otherwise provided herein, this Subscription Agreement shall not confer any rights or remedies upon any person
other than the parties hereto, and their respective successors and assigns, and the parties hereto acknowledge that such persons so referenced
are third party beneficiaries of this Subscription Agreement with right of enforcement for the purposes of, and to the extent of, the
rights granted to them, if any, pursuant to the applicable provisions.

 

(h)           Except
as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto and
their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements,
representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such
heirs, executors, administrators, successors, legal representatives and permitted assigns.

 

    16

     

    

 

(i)            If
any provision of this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or unenforceable,
the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected
or impaired thereby and shall continue in full force and effect.

 

(j)             This
Subscription Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf) and by different
parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed
and delivered shall be construed together and shall constitute one and the same agreement.

 

(k)            The parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions of
this Subscription Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed
that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Subscription Agreement, without posting
a bond or undertaking and without proof of damages, to enforce specifically the terms and provisions of this Subscription Agreement, this
being in addition to any other remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise.

 

(l)            If any change in the number, type or classes of authorized shares of SPAC (including the Shares), other than as contemplated
by the BCA or any agreement contemplated by the BCA, shall occur between the date hereof and immediately prior to the Closing by reason
of reclassification, recapitalization, stock split (including reverse stock split) or combination, exchange or readjustment of shares,
or any stock dividend, the number of Shares issued to the Investor and the Per Share Purchase Price shall be appropriately adjusted to
reflect such change.

 

(m)           This
Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (regardless of the laws
that might otherwise govern under applicable principles of conflicts of laws thereof) as to all matters (including any action, suit,
litigation, arbitration, mediation, claim, charge, complaint, inquiry, proceeding, hearing, audit, investigation or reviews by or before
any governmental entity related hereto), including matters of validity, construction, effect, performance and remedies.

 

(n)           Each
party hereto hereby, and any person asserting rights as a third party beneficiary may do so only if he, she or it, irrevocably
agrees that any action, suit or proceeding between or among the parties hereto, whether arising in contract, tort or otherwise,
arising in connection with any disagreement, dispute, controversy or claim arising out of or relating to this Subscription Agreement
or any related document or any of the transactions contemplated hereby or thereby (“Legal Dispute”) shall be
brought only to the exclusive jurisdiction of the courts of the State of Delaware or the federal courts located in the State of
Delaware, and each party hereto hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts
therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that
it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such
suit, action or proceeding that is brought in any such court has been brought in an inconvenient forum. During the period a Legal
Dispute that is filed in accordance with this Section 11(n) is pending before a court, all actions, suits or proceedings with
respect to such Legal Dispute or any other Legal Dispute, including any counterclaim, cross-claim or interpleader, shall be subject
to the exclusive jurisdiction of such court. Each party hereto and any person asserting rights as a third party beneficiary may do
so only if he, she or it hereby waives, and shall not assert as a defense in any Legal Dispute, that (i) such party is not
personally subject to the jurisdiction of the above named courts for any reason, (ii) such action, suit or proceeding may not
be brought or is not maintainable in such court, (iii) such party’s property is exempt or immune from execution,
(iv) such action, suit or proceeding is brought in an inconvenient forum, or (v) the venue of such action, suit or
proceeding is improper. A final judgment in any action, suit or proceeding described in this Section 11(n) following the expiration
of any period permitted for appeal and subject to any stay during appeal shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by applicable laws. EACH OF THE PARTIES HERETO AND ANY PERSON
ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY MAY DO SO ONLY IF HE, SHE OR IT IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO
TRIAL BY JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM RELATING THERETO. IF THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE
IN WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL
ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY. FURTHERMORE, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL
SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT BE
WAIVED.

 

    17

     

    

 

(o)           Any
notice or communication required or permitted hereunder to be given to a party hereto shall be in writing and either delivered personally,
emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, to such
address(es) or email address(es) set forth on the signature page hereto, and shall be deemed to be given and received (i) when so delivered
personally, (ii) when sent, with no mail undeliverable or other rejection notice, if sent by email, or (iii) three (3) business days
after the date of mailing to the address below or to such other address or addresses as the party may hereafter designate by notice given
hereunder:

 

(i)                 
if to Investor, to such address(es) or email address(es) as set forth herein;

 

(ii)               
if to SPAC, to:

 

Montes Archimedes
Acquisition Corp.

724 Oak Grove, Suite
130

Menlo Park, CA 94025

Attention: Maria Walker

E-mail:        maria@patientsquarecapital.com

 

with a copy (which
shall not constitute notice) to:

 

Kirkland & Ellis
LLP

601 Lexington Avenue

New York, NY 10022

Attention:  Michael
E. Weisser, P.C.

   Ryan Brissette

E-mail:       michael.weisser@kirkland.com

    ryan.brissette@kirkland.com

 

(iii)           
if to the Company, to:

 

Roivant Sciences Ltd.

Suite 1, 3rd Floor,

11-12 St. James’s
Square,

London SW1Y 4LB

United Kingdom

Attention: Matthew
Gline

E-mail:       matthew.gline@roivant.com

   legalnotices@roivant.com

 

with a copy (which
shall not constitute notice) to:

 

Roivant Sciences,
Inc.

151 West 42nd Street,
15th Floor

New York, NY 10036

Attention:  General
Counsel

E-mail:        jo.chen@roivant.com

 

    18

     

    

 

-and-

 

Davis Polk & Wardwell
LLP

450 Lexington Avenue

New York, NY 10017

Attention: Derek Dostal

    Brian Wolfe

    Lee Hochbaum

E-mail:       derek.dostal@davispolk.com

    brian.wolfe@davispolk.com

    lee.hochbaum@davispolk.com

 

12.            Non-Reliance
and Exculpation. The Investor acknowledges that it is not relying upon, and has not relied upon, any statement, representation or
warranty made by any person, firm or corporation (including, without limitation, the Placement
Agents, any of their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives
of any of the foregoing), other than the statements, representations and warranties of SPAC and the Company expressly contained in Section
5 and Section 6 of this Subscription Agreement, respectively, in making its investment or decision to invest in SPAC. The Investor acknowledges
and agrees that none of (i) any other investor pursuant to this Subscription Agreement or any other subscription agreement related to
the private placement of the Shares (including the investor’s respective affiliates or any control persons, officers, directors,
employees, partners, agents or representatives of any of the foregoing), (ii) the Placement Agents,
their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the
foregoing, or (iii) any other party to the BCA or any Non-Party Affiliate (other than SPAC or the Company with respect to the
previous sentence), shall have any liability to the Investor, or to any other investor, pursuant to, arising out of or relating to this
Subscription Agreement or any other subscription agreement related to the private placement of the Shares, the negotiation hereof or
thereof or its subject matter, or the transactions contemplated hereby or thereby, including, without limitation, with respect to any
action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Shares or with respect
to any claim (whether in tort, contract or otherwise) for breach of this Subscription Agreement or in respect of any written or oral
representations made or alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged inaccuracies,
misstatements or omissions with respect to any information or materials of any kind furnished by SPAC, the Company, the Placement Agents
or any Non-Party Affiliate concerning SPAC, the Company, the Placement Agents, any of their controlled affiliates, this Subscription
Agreement or the transactions contemplated hereby. For purposes of this Subscription Agreement, “Non-Party Affiliates” means
each former, current or future officer, director, employee, partner, member, manager, direct or indirect equityholder or affiliate of
SPAC, the Company, the Placement Agents or any of SPAC’s, the Company’s or the Placement Agents’ controlled affiliates
or any family member of the foregoing.

 

13.                Disclosure.
SPAC shall, by 9:00 a.m., New York City time, on the first (1st) business day immediately following the date of this Subscription
Agreement, issue one or more press releases or file with the SEC a Current Report on Form 8-K (collectively, the “Disclosure
Document”) disclosing all material terms of the transactions contemplated hereby and by the Other Subscription Agreements, the
Transaction and any other material, nonpublic information that SPAC has provided to the Investor at any time prior to the filing of
the Disclosure Document. Upon the issuance of the Disclosure Document, to the actual knowledge of SPAC, the Investor shall not be in
possession of any material, non-public information received from SPAC or any of its officers, directors, or employees or agents
(including the Placement Agents), and the Investor shall no longer be subject to any confidentiality or similar obligations under
any current agreement, whether written or oral, with SPAC or any of its affiliates, relating to the transactions contemplated by
this Subscription Agreement. Notwithstanding anything in this Subscription Agreement to the contrary, neither SPAC nor the Company
shall publicly disclose the name of the Investor or any of its affiliates or advisers, or include the name of the Investor or any of
its affiliates or advisers without the prior written consent of the Investor (a) in any press release or marketing materials or (b)
in any filing with the SEC or any regulatory agency or trading market except (i) as required by the federal securities law or
pursuant to other routine proceedings of regulatory authorities, (ii) to the extent such disclosure is required by law, at the
request of the staff of the SEC or regulatory agency or under the regulations of any national securities exchange on which
SPAC’s securities are listed for trading or (iii) to the extent such announcements or other communications contain only
information previously disclosed in a public statement, press release or other communication previously approved in accordance with
this Section 13; provided that, in each case of (i), (ii), or (iii), SPAC will provide the Investor with written notice
(including by e-mail) of any such disclosure and shall reasonably consult with Investor regarding such disclosure.

 

    19

     

    

 

14.           Separate
Obligations. For the avoidance of doubt, all obligations of the Investor hereunder are separate and several from the obligations
of any Other Investor. The decision of Investor to purchase the Shares pursuant to this Subscription Agreement has been made by Investor
independently of any Other Investor or any other investor and independently of any information, materials, statements or opinions as
to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects
of SPAC, the Company, or any of their respective subsidiaries which may have been made or given by any Other Investor or investor or
by any agent or employee of any Other Investor or investor, and neither Investor nor any of its agents or employees shall have any liability
to any Other Investor or investor (or any other person) relating to or arising from any such information, materials, statements or opinions.
Nothing contained herein or in any Other Subscription Agreement, and no action taken by Investor or Other Investors pursuant hereto or
thereto, shall be deemed to constitute Investor and Other Investor or other investors as a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that Investor and Other Investors or other investors are in any way acting in concert
or as a group with respect to such obligations or the transactions contemplated by this Subscription Agreement and the Other Subscription
Agreements. The Investor acknowledges that no Other Investor has acted as agent for Investor in connection with making its investment
hereunder and no Other Investor will be acting as agent of Investor in connection with monitoring its investment in the Shares or enforcing
its rights under this Subscription Agreement. The Investor shall be entitled to independently protect and enforce its rights, including
without limitation the rights arising out of this Subscription Agreement, and it shall not be necessary for any Other Investor or investor
to be joined as an additional party in any proceeding for such purpose.

 

15.           Massachusetts
Business Trust. If Investor is a Massachusetts Business Trust, a copy of the Declaration of Trust of Investor or any affiliate thereof
is on file with the Secretary of State of the Commonwealth of Massachusetts and notice is hereby given that the Subscription Agreement
is executed on behalf of the trustees of Investor or any affiliate thereof as trustees and not individually and that the obligations
of the Subscription Agreement are not binding on any of the trustees, officers or stockholders of Investor or any affiliate thereof individually
but are binding only upon Investor or any affiliate thereof and its assets and property.

 

[SIGNATURE PAGES
FOLLOW]

 

    20

     

    

 

IN WITNESS WHEREOF, the Investor has executed
or caused this Subscription Agreement to be executed by its duly authorized representative as of the date set forth below.

 

	Name of Investor:	 	State/Country of Formation or Domicile:
	 	 	 
	By:		 	 
	Name:		 	 
	Title: 		 	 
	 		 	 
	Name in which Shares are to be registered (if different):	 	Date: ________, 2021
	 	 	 
	Investor’s EIN:	 	 
	 	 	 
	Business Address-Street:	 	Mailing Address-Street (if different):
	 	 	 
	City, State, Zip:	 	City, State, Zip:
	 	 	 
	Attn:		 	Attn:	
	 	 	 	 	 
	Telephone No.:	 	Telephone No.:
	Facsimile No.:	 	Facsimile No.:
	 	 	 
	
    Email:

     

    Number of Shares subscribed for:

     
	 	 
	Aggregate Subscription Amount: $	 	Price Per Share: $10.00

 

You must pay the Subscription Amount by wire transfer
of United States dollars in immediately available funds to the account specified by SPAC in the Closing Notice.

 

    

     

    

 

IN WITNESS WHEREOF, the undersigned has accepted
this Subscription Agreement as of the date set forth below.

 

	 	MONTES ARCHIMEDES ACQUISITION CORP.
	 	 
	 	By:	
	 	Name:
	 	Title:
	 	 
	 	ROIVANT SCIENCES LTD.
	 	 
	 	By:	
	 	Name:
	 	Title:
	 	 
	Date:
                 , 2021	

 

    

     

    

 

SCHEDULE A

 

 

ELIGIBILITY REPRESENTATIONS
OF THE INVESTOR

 

	A.	QUALIFIED INSTITUTIONAL BUYER STATUS

 

	 	(Please check the applicable subparagraphs):

 

        ̈  We
are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act (a “QIB”)).

 

        ̈  We are subscribing for the Shares
as a fiduciary or agent with full investment discretion for one or more investor accounts, and each owner of such account is a QIB.

 

** OR **

 

	B.	INSTITUTIONAL ACCREDITED INVESTOR STATUS

 

	 	(Please check the applicable subparagraphs):

 

	 	1.	 ̈  We are an “accredited investor” (within the meaning of Rule 501(a) under the Securities Act or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act), and have marked and initialed the appropriate box on the following page indicating the provision under which we qualify as an “accredited investor.”

 

	 	2.	 ̈  We are not a natural person.

 

Rule 501(a), in relevant part, states that
an “accredited investor” shall mean any person who comes within any of the below listed categories, or who the issuer reasonably
believes comes within any of the below listed categories, at the time of the sale of the securities to that person. The Investor has indicated,
by marking and initialing the appropriate box below, the provision(s) below which apply to the Investor and under which the Investor accordingly
qualifies as an “accredited investor.”

 

 ̈  Any
bank, registered broker or dealer, insurance company, registered investment company, business development company, or small business investment
company;

 

 ̈  Any plan established
and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for
the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

 ̈  Any employee benefit
plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank, insurance company, or registered investment
adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000;

 

 ̈  Any
organization described in section 501(c)(3) of the Internal Revenue Code, corporation, similar business trust, or partnership, not
formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;

 

 ̈  Any trust with assets
in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is directed by a sophisticated person; or

 

 ̈  Any
entity in which all of the equity owners are accredited investors meeting one or more of the above tests.

 

** AND **

 

    

     

    

 

	C.	AFFILIATE STATUS
	 	 
	 	(Please check the applicable subparagraphs):  
	 	 
	 	 ̈  We are:
	 	 
	 	 ̈  We are not:
	 	 
	 	 an “affiliate” (as defined in Rule 144 under the Securities Act) of the SPAC
or acting on behalf of an affiliate of the SPAC.  
	 	 
	 	** AND **
	 	 
	D.	   QUALIFIED PURCHASER STATUS

 

	 	(Please check the applicable subparagraphs):
 

                FOR INDIVIDUALS:

                 

	 	1.	 ̈  A natural person who owns not less than U.S.$5,000,000 in investments.  For this purpose, investments owned by the Investor include all investments that are the Investor’s separate property and any investments held jointly with the Investor’s spouse, as community property or otherwise, but do not include investments that are the separate property of the Investor’s spouse unless the interest will be a joint investment of the Investor and the Investor’s spouse.

 

	 	2.	 ̈  A natural person who has discretionary investment authority with regard
to at least U.S.$25,000,000 of investments, including for this purpose solely the Investor’s own investments and investments of
third parties that are themselves accurately described by one or more paragraphs of this Section D.

 

	 	
    (Please check the applicable subparagraphs):

     

    FOR ENTITIES:

     

 

	 	3.	 ̈  A corporation, partnership, limited liability company, trust or other organization that:  (i) was not organized or reorganized and is not operated for the specific purpose of acquiring the interest or any other interest in SPAC, and less than 40% of the assets of which will consist of interests in SPAC (calculated as of the time of the Investor’s execution of this Subscription Agreement); (ii) owns not less than U.S.$5,000,000 in investments; and (iii) is owned directly or indirectly solely by or for two or more natural persons who are related as siblings or spouses (including former spouses), or direct lineal descendants by birth or adoption, spouses of such persons, the estates of such persons, or foundations, charitable organizations, or trusts established by or for the benefit of such persons.

 

	 	4.	 ̈  A trust:  (i) that is not described in paragraph (3) of this Section
D; (ii) that was not organized or reorganized and is not operated for the specific purpose of acquiring the interest or any other interest
in SPAC, and less than 40% of the assets of which will consist of interests in SPAC (calculated as of the time of the Investor’s
execution of this Subscription Agreement); and (iii) with respect to which each of the settlors and other contributors of assets, trustees,
and other authorized decision makers is a person described in paragraph (1), (2), (3) or (4) of this Section D.

 

	 	5.	 ̈ An entity that:  (i) was not organized or
reorganized and is not operated for the specific purpose of acquiring the interest or any other interest in SPAC, and less than 40% of
the assets of which will consist of interests in SPAC (calculated as of the time of the Investor’s execution of this Subscription
Agreement); and (ii) has discretionary investment authority with regard to at least U.S.$25,000,000 of investments, whether for its own
account or for the account of other persons that are themselves accurately described by one or more other paragraphs of this Section
D.

 

    24

     

    

 

	   	 6.	 ̈ An entity, each and every beneficial owner of which is a person accurately described
by one or more of the foregoing paragraphs of this Section D or is itself an entity each and every beneficial owner of which is a person
accurately described by one or more of the foregoing paragraphs of this Section D.  If the Investor is a qualified purchaser
solely for the reason described in this paragraph 6, the Investor shall, at the request of SPAC, submit to SPAC a separate qualified
purchaser questionnaire for each beneficial owner of the Investor’s securities.

 

This page should
be completed by the Investor

and constitutes
a part of the Subscription Agreement.

 

    25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]